bluebird bio Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Operational Progress

bluebird bio Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Operational Progress

CAMBRIDGE, Mass.–(BUSINESS WIRE)–
bluebird bio, Inc. (NASDAQ:BLUE) today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2020 and shared recent operational progress.

“For over ten years, bluebird bio has been pioneering gene therapies for patients with rare diseases and cancer, and our work continues with the analysis of the recent safety events identified in our HGB-206 study in patients with sickle cell disease. We have seen the transformative benefit of these therapies and are conducting a scientific and medical investigation to best inform our path forward on behalf of the patients we hope to serve with LentiGlobin,” said Nick Leschly, chief bluebird. “While this work is ongoing, we remain focused on the upcoming PDUFA action due date for ide-cel for multiple myeloma next month, the potential EU approval of eli-cel for CALD mid-year and the planned US filings for β-thalassemia and CALD later in the year. Through these challenges, we are keeping patients at the center and were very excited to reach a major milestone of the first commercial infusion of ZYNTEGLO in Germany earlier this month.”

RECENT HIGHLIGHTS

COMPANY

  • CLINICAL HOLD OF PHASE 1/2 AND PHASE 3 STUDIES OF LENTIGLOBIN GENE THERAPY FOR SICKLE CELL DISEASEAND TEMPORARY SUSPENSION OF MARKETING OF ZYNTEGLO IN EUROPE – On February 16, 2021, bluebird bio announced that due to a Suspected Unexpected Serious Adverse Reaction (SUSAR) of acute myeloid leukemia and a SUSAR of myelodysplastic syndrome in our HGB-206 clinical study, the FDA has placed our clinical studies of LentiGlobin for SCD on clinical hold. We are investigating these events and plan to continue to work closely with the FDA in their review of these events. In addition, we are also engaged with the EMA in discussions regarding our proposed development plans for LentiGlobin for SCD in Europe. In light of these SUSARs, we have temporarily suspended marketing of ZYNTEGLO in Europe. Additionally, the EMA has paused the renewal procedure for ZYNTEGLO’s conditional marketing authorization while the EMA’s pharmacovigilance risk assessment committee reviews the risk-benefit assessment for ZYNTEGLO and determines whether any additional pharmacovigilance measures are necessary.
  • INTENT TO SEPARATE On January 11, 2021, bluebird bio announced its intent to separate its severe genetic disease and oncology businesses into two independent, publicly traded companies (bluebird bio and “Oncology Newco”). The separation is expected to be completed by year-end 2021 and it is anticipated that the spin out of Oncology Newco is to be tax-free to shareholders, subject to receipt of a favorable Internal Revenue Service (IRS) ruling.
    • Following the separation, bluebird bio intends to focus on delivery of its Core 3 therapies in β-thalassemia, cerebral adrenoleukodystrophy and sickle cell disease, expand access and reimbursement for our commercial product, ZYNTEGLO, in Europe and continue to explore innovative tools and technologies to ultimately bring these transformative medicines to more patients.
    • Following the separation, Oncology Newco plans to support commercial success of ide-cel and continued development of bb21217, deliver on the oncology pipeline of cellular therapies with a focus on non-Hodgkin’s lymphoma, acute myeloid leukemia, next-generation multiple myeloma and solid tumors and advance next generation product cycling engine with an overarching goal of 1-2 investigational new drugs (INDs) in each of the years 2021 and 2022.
    • At the time of separation, bluebird bio plans to capitalize each business with sufficient capital to achieve value creating milestones and intends to provide additional financial details closer to the date of separation.

TRANSFUSION DEPENDENT β-THALASSEMIA

  • FIRST PATIENT TREATED WITH ZYNTEGLO GENE THERAPY – bluebird bio is announcing today that a patient was treated earlier this month with the first commercial infusion of ZYNTEGLO [betibeglogene autotemcel (beti-cel)]. The patient was treated at a Qualified Treatment Center (QTC) in Germany.
  • TDT DATA AT ASH – On December 5, 2020, bluebird bio presentednew data showing that all patients that achieved transfusion independence continue to remain free from transfusions up to six years in the ongoing long-term follow-up study (LTF-303) of beti-cel gene therapy in patients with TDT at the 62nd American Society of Hematology (ASH) Annual Meeting. The company also presented updated efficacy and safety results for pediatric patients in the Phase 3 HGB-207 (Northstar-2) and HGB-212 (Northstar-3) studies.

SICKLE CELL DISEASE

  • FIRST PATIENT TREATED IN CONFIRMATORY HGB-210 STUDY –bluebird bio is announcing today that within the first quarter, the first patient was infused in HGB-210, a Phase 3 confirmatory study of LentiGlobin™gene therapy (bb1111) for adults and pediatric subjects ≥2 and ≤50 years of age with sickle cell disease (SCD).
  • SCD DATA AT ASH – On December 7, 2020, bluebird bio presented new data showing a complete elimination of severe vaso-occlusive events (VOEs) through 24 months of follow-up in patients who had a history of at least four severe VOEs and at least six months follow-up in Group C of its ongoing Phase 1/2 HGB-206 study of bb1111 for patients with SCD at the 62nd ASH Annual Meeting.
  • MAGENTA COLLABORATION – On December 4, 2020, bluebird bio and Magenta Therapeutics announced an exclusive clinical trial collaboration to evaluate the utility of MGTA-145, in combination with plerixafor, for mobilization and collection of stem cells in patients with SCD. The combination approach has the potential to achieve safe, rapid and reliable mobilization of sufficient quantities of high-quality stem cells to ultimately improve outcomes associated with stem cell transplantation. The companies will co-fund the clinical trial and Magenta will retain all rights to its product candidate.

MULTIPLE MYELOMA

  • CRB-401 DATA AT ASH – On December 5, 2020, bluebird bio and Bristol-Myers Squibb presented longer-term results showing ongoing deep and durable responses in the original Phase 1 study (CRB-401) of the companies’ investigational B-cell maturation antigen (BCMA) directed chimeric antigen receptor (CAR) T cell therapy, idecabtagene vicleucel (ide-cel), in patients with relapsed and refractory multiple myeloma at the 62nd ASH Annual Meeting.
  • BB21217 DATA AT ASH – On December 5, 2020, bluebird bio and Bristol-Myers Squibb presented updated safety and efficacy results showing promising response rates and durability from the ongoing Phase 1 study (CRB-402) of bb21217, an investigational BCMA-directed CAR T cell therapy in patients with relapsed and refractory multiple myeloma at the 62nd ASH Annual Meeting. The company announced the study has completed enrollment and follow-up is ongoing as data continue to mature and the durability of response at the recommended phase 2 dose is assessed.

UPCOMING ANTICIPATED MILESTONES

Regulatory Outlook

  • Multiple Myeloma: The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of March 27, 2021 for the approval of ide-cel (bb2121) in patients with relapsed and refractory multiple myeloma.
  • SCD: The company is investigating the recently-reported safety events and plans to continue to work closely with the FDA in their review of these events to provide an update on the Company’s development plan and timeline for submission for regulatory approval.
  • TDT: The company is on track to complete its rolling BLA submission to the U.S. FDA for beti-cel in mid-2021, contingent upon successful resolution of any U.S. FDA concerns applicable to the program arising out of the recently-reported safety events in the SCD program. This submission is anticipated to include patients with transfusion dependent β-thalassemia across all genotypes (including non-β0/β0 genotypes and β0/β0 genotypes).
  • CALD: The company is on track to complete its BLA submission to the U.S. FDA for elivaldogene autotemcel (eli-cel) in mid-2021. The company plans to receive European approval for eli-cel in patients with cerebral adrenoleukodystrophy (CALD) in mid-2021.

Clinical Updates and Milestones

  • Updated data from ongoing clinical study in patients with SCD by the end of 2021.
  • Updated data from ongoing clinical studies in patients with TDT in mid-2021.
  • Updated data from ongoing clinical studies in patients with CALD in mid-2021.
  • bb21217 clinical data from the ongoing CRB-402 study in patients with multiple myeloma by the end of 2021.
  • Submission of 1 – 2 investigational new drug (IND) applications by the end of 2021.

FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS

  • Cash Position: Cash, cash equivalents and marketable securities as of December 31, 2020 and December 31, 2019 were $1.27 billion and $1.24 billion, respectively. The increase in cash, cash equivalents and marketable securities is primarily a result of proceeds received from the May 2020 public offering of the Company’s common stock and a one-time upfront payment received in connection with the Company’s amended collaboration with BMS, partially offset by cash used in support of ordinary course operating and commercial-readiness activities.
  • Revenues: Total revenues were $10.7 million for the three months ended December 31, 2020 compared to $10.0 million for the three months ended December 31, 2019. Total revenues were $250.7 million for the twelve months ended December 31, 2020 compared to $44.7 million for the twelve months ended December 31, 2019. The increase for the three-month period was primarily driven by an increase in royalty and other revenue. The increase for the twelve-month period was primarily driven by the amended BMS collaboration and monetization for ex-U.S. milestones and royalties from ide-cel and bb21217, with the majority of the revenue recognized relating to ide-cel license and manufacturing services.
  • R&D Expenses: Research and development expenses were $137.1 million for the three months ended December 31, 2020 compared to $161.8 million for the three months ended December 31, 2019. Research and development expenses were $588.0 million for the twelve months ended December 31, 2020 compared to $582.4 million for the twelve months ended December 31, 2019. The decrease for the three-month period was primarily driven by a decrease in manufacturing costs, partially offset by increased costs incurred through the amended BMS collaboration. The increase for the twelve-month period was primarily driven by an overall increase in costs incurred to advance and expand the company’s pipeline, partially offset by a decrease in manufacturing costs.
  • SG&A Expenses: Selling, general and administrative expenses were $77.0 million for the three months ended December 31, 2020 compared to $76.2 million for the three months ended December 31, 2019. Selling, general and administrative expenses were $286.9 million for the twelve months ended December 31, 2020 compared to $271.4 million for the twelve months ended December 31, 2019. The increase for both periods was largely attributable to increased headcount and costs incurred to support the Company’s ongoing operations and growth of its pipeline, partially offset by a decrease in costs related to commercial readiness activities due to delays during 2020 as a result of the COVID-19 pandemic.
  • Net Loss: Net loss was $199.9 million for the three months ended December 31, 2020 compared to $223.3 million for the three months ended December 31, 2019. Net loss was $618.7 million for the twelve months ended December 31, 2020 compared to $789.6 million for the twelve months ended December 31, 2019.

About bluebird bio, Inc.

bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., headquarters, we’re developing gene and cell therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. Beyond our labs, we’re working to positively disrupt the healthcare system to create access, transparency and education so that gene therapy can become available to all those who can benefit.

bluebird bio is a human company powered by human stories. We’re putting our care and expertise to work across a spectrum of disorders: cerebral adrenoleukodystrophy, sickle cell disease, β-thalassemia and multiple myeloma, using gene and cell therapy technologies including gene addition, and (megaTAL-enabled) gene editing.

bluebird bio has additional nests in Seattle, Wash.; Durham, N.C.; and Zug, Switzerland. For more information, visit bluebirdbio.com.

Follow bluebird bio on social media: @bluebirdbio, LinkedIn, Instagram and YouTube.

ZYNTEGLO, LentiGlobin, and bluebird bio are trademarks of bluebird bio, Inc.

Forward-Looking Statements

This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the company’s financial condition, results of operations, as well as statements regarding the Company’s timing and expectations regarding its investigation of the relationship of the safety events in HGB-206 to the use of lentiviral vector BB305 in LentiGlobin gene therapy for SCD, and any myeloablation regimen used in connection with treatment; the plans for regulatory submissions for beti-cel (marketed as ZYTENGLO in the European Union), eli-cel, ide-cel, and LentiGlobin for SCD, including anticipated endpoints to support regulatory submissions and timing expectations; the company’s expectations regarding the potential for the suspension-based manufacturing process for lentiviral vector; the company’s expectations and execution under its revised operating plan, including its cash runway; its expectations for commercialization efforts for ZYNTEGLO in Europe; and the company’s expectations for the amended collaboration agreement with BMS; as well as the company’s intentions regarding the timing for providing further updates on the development and commercialization of ZYNTEGLO and the company’s product candidates; the timing, leadership, structure, including the division of assets among bluebird bio and Oncology Newco, and the impact of a separation; as well as the company’s intention to provide further updates on the separation and the related financing strategies for bluebird bio and Oncology Newco; and the tax free nature of the separation. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the Company may not be able to definitively determine whether the lentiviral vector BB305 used in LentiGlobin gene therapy for SCD and in beti-cel is related to the safety events in a timely manner, or at all; the risk that the lentiviral vector BB305 has caused insertional oncogenic events, including acute myeloid leukemia; the risk that insertional oncogenic events associated with lentiviral vector or additional safety events associated with myeloablation will be discovered or reported over time; the risk that we may not be able to address regulatory authorities’ concerns quickly or at all and may not be able to resume our HGB-206 or HGB-210 studies in a timely manner, or at all; the risk that we may not resume patient treatment with ZYNTEGLO in the commercial context in a timely manner or at all; the risk that our lentiviral vector platform across our severe genetic disease programs may be implicated, affecting the development and potential approval elivaldogene autotemcel; the risks that we may not complete the separation on the terms or timeline currently contemplated if at all, achieve the expected benefits of a separation, and a separation could harm our business, results of operations and financial condition; the risk that the transaction might not be tax-free; we may be unable to make, on a timely or cost-effective basis, the changes necessary to operate as independent companies; Oncology Newco’s lack of independent operating history and the risk that its accounting and other management systems may not be prepared to meet the financial reporting and other requirements of operating as an independent public company; dedicated financial and/or strategic funding sources may not be available on favorable terms; a separation or announcement thereof may adversely impact our ability to attract or retain key personnel; a separation may adversely impact the effectiveness of development and commercialization efforts by us and our partners; our businesses may be disrupted as a result of the announcement or pendency of the separation; the COVID-19 pandemic and resulting economic conditions will have a greater impact on the company’s operations and plans than anticipated; that our amended collaboration with BMS will not continue or be successful; that preliminary positive efficacy and safety results from our prior and ongoing clinical trials will not continue or be repeated in our ongoing or future clinical trials; the risk that our plans for submitting a BLA for LentiGlobin for SCD may be delayed if the FDA does not accept our comparability plans for the use of the suspension-based manufacturing process for LVV; the risk that the BLA for ide-cel is approved by the FDA in the timeline we expect, or at all; the risk of cessation or delay of any of the ongoing development activities, including clinical studies, and commercialization efforts due to delays from the COVID-19 pandemic’s impact on healthcare systems; the risk that the current or planned clinical trials of our product candidates will be insufficient to support regulatory submissions or marketing approval in the United States and European Union; the risk that regulatory authorities will require additional information regarding our product candidates, resulting in delay to our anticipated timelines for regulatory submissions, including our applications for marketing approval; the risk that we will encounter challenges in the commercial launch of ZYNTEGLO in the European Union, including in managing our complex supply chain for the delivery of drug product, or in obtaining sufficient coverage or reimbursement for our products; and the risk that any one or more of our product candidates, will not be successfully developed, approved or commercialized. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in our most recent Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and bluebird bio undertakes no duty to update this information unless required by law.

bluebird bio, Inc.

Condensed Consolidated Statements of Operations

(in thousands, except per share data)

(unaudited)

 

 

 

For the three months ended

December 31,

 

For the twelve months ended

December 31,

 

 

2020

 

2019

 

2020

 

2019

Revenue:

 

 

 

 

 

 

 

 

Service revenue

 

$

5,522

 

 

$

5,827

 

 

$

114,064

 

 

$

30,729

 

Collaborative arrangement revenue

 

1,196

 

 

1,332

 

 

115,594

 

 

5,740

 

Royalty and other revenue

 

3,990

 

 

2,838

 

 

21,076

 

 

8,205

 

Total revenues

 

10,708

 

 

9,997

 

 

250,734

 

 

44,674

 

Operating expenses:

 

 

 

 

 

 

 

 

Research and development

 

137,094

 

 

161,821

 

 

587,956

 

 

582,413

 

Selling, general and administrative

 

76,974

 

 

76,202

 

 

286,896

 

 

271,362

 

Cost of royalty and other revenue

 

1,499

 

 

1,073

 

 

5,396

 

 

2,978

 

Change in fair value of contingent consideration

 

(877

)

 

1,435

 

 

(6,468

)

 

2,747

 

Total operating expenses

 

214,690

 

 

240,531

 

 

873,780

 

 

859,500

 

Loss from operations

 

(203,982

)

 

(230,534

)

 

(623,046

)

 

(814,826

)

Interest income, net

 

1,281

 

 

6,855

 

 

11,539

 

 

34,761

 

Other income (expense), net

 

3,080

 

 

535

 

 

(6,502

)

 

(10,088

)

Loss before income taxes

 

(199,621

)

 

(223,144

)

 

(618,009

)

 

(790,153

)

Income tax (expense) benefit

 

(253

)

 

(203

)

 

(686

)

 

545

 

Net loss

 

$

(199,874

)

 

$

(223,347

)

 

$

(618,695

)

 

$

(789,608

)

Net loss per share – basic and diluted:

 

$

(3.01

)

 

$

(4.04

)

 

$

(9.95

)

 

$

(14.31

)

Weighted-average number of common shares used in computing net loss per share – basic and diluted:

 

66,395

 

 

55,344

 

 

62,178

 

 

55,191

 

bluebird bio, Inc.

Condensed Consolidated Balance Sheet Data

(in thousands, except per share data)

(unaudited)

 

 

 

As of

December 31,

2020

 

As of

December 31,

2019

Cash, cash equivalents and marketable securities

 

$

1,274,142

 

$

1,237,966

Total assets

 

$

1,781,252

 

$

1,727,424

Total liabilities

 

$

426,196

 

$

442,431

Total stockholders’ equity

 

$

1,355,056

 

$

1,284,993

 

Investors & Media

Investors:

Ingrid Goldberg, 857-217-0490

[email protected]

Elizabeth Pingpank, 617-914-8736

[email protected]

Media:

Jenn Snyder, 617-448-0281

[email protected]

Catherine Falcetti, 617-583-3411

[email protected]

KEYWORDS: United States North America Canada Massachusetts

INDUSTRY KEYWORDS: Oncology Health Genetics Pharmaceutical Cardiology Biotechnology

MEDIA:

Logo
Logo

XP Inc. Reports 4Q20 Financial Results

XP Inc. Reports 4Q20 Financial Results

SÃO PAULO, Brazil–(BUSINESS WIRE)–
XP Inc. (NASDAQ:XP) (“XP” or the “Company”), a leading tech-enabled platform and a trusted pioneer in providing low-fee financial products and services in Brazil, today reported its financial results for the fourth quarter of 2020 and for the year ended December 31, 2020.

To our shareholders:

The events of 2020 were certainly demanding for all of us around the world. Faced with a pandemic of unimaginable proportions, we collectively became more resilient, supportive, flexible and aware that nothing can be taken for granted. Amid the catastrophic health crisis and the reality of quarantine, we reflected and reviewed the way we relate to our family, work, routine and old habits. After many challenges, we remain confident that better days are ahead.

2020 marked XP Inc.’s first as a publicly traded company, which presented new challenges in internal and external communications, governance and strategy. We have, undeniably become a better and more prepared company for the future since our IPO in December 2019.

I am convinced that our culture, which I consider our greatest asset and a key long-term competitive advantage, has been tested, strengthened and, without a doubt, was the main factor in successfully navigating this turbulent period and driving robust growth.

I want to reinforce our values that we believe will allow all our employees to help transform the financial markets in Brazil and improve peoples’ lives over time:

Dream Big – to continue to believe in “impossible” projects and build the bridges to make them possible.

Open Mind – to never forget that there are no absolute truths, that mistakes are part of the journey and that great ideas and projects often come from where and when you least expect them.

Entrepreneurial Spirit – to turn employees into owners of the company, with responsibilities to maintain the company’s competitive and ethical standards, and free from hierarchical limitations.

After 2020, I am convinced that the result of our values in practice is greater than the sum of the three separate parts, and I would like to share some concrete examples of how we have evolved during the year.

Almost twelve months ago, at the beginning of the crisis, we experienced an unprecedented increase in trading volumes across our platforms. This allowed us to solve operational bottlenecks and anticipate investments in technology to guarantee the availability and robustness of services for our customers. We are proud of the improvements we have achieved in a short period of time, which have resulted in expanded capacity to manage new levels of demand. Even more remarkable is the fact that the entire team working on this has been working from home and, therefore, with a greater need for creativity, intensity and strong communication.

We have also made significant progress on our ESG initiatives, accelerated by the pandemic that severely impacted the most disadvantaged part of the population in our country. We created the “Juntos Transformamos” movement, with the goal of delivering food and medical equipment quickly and effectively to the people who need it most, serving approximately 500,000 people thus far. Going forward, we are committed to leading by example and seeking to leave a better country for future generations. We created our ESG board and will strive to become an ESG reference, generating relevant and long-term impacts on society. Rest assured that this will be a recurring theme in our communications and one of our key priorities for years to come.

Additionally, during 2020 we learned new ways to work as a team without necessarily being together physically. As a result, the XP Anywhere concept was born – permanent adoption of the flexible work model – as well as the Villa XP project, a sustainable and innovative space for XP employees, partners and clients. These initiatives will provide a better quality of life for our employees and their families, avoiding traffic and large displacements, allowing them to live outside large corporate centers and consequently enhancing commitment and performance. Also, we improved our ability to attract talent in Brazil and around the world and significantly lower our cost structure, which will drive significant benefits in terms of efficiency and long-term profitability.

Throughout last year, we experienced significant digital acceleration. In this context, we revisited our long-term strategic planning and the pace with which we intend to address new markets and target new customers. The expected launches of our digital bank and credit card business, along with our recently available collateralized loan products, will enhance customer experience and drive expanded relationships.

In terms of operating and financial results, we had the best year in our history. We generated gross revenue of R$8.7 billion, an increase of 58% Y-o-Y. Our Adjusted Net Income totaled R$2.3 billion, an increase of 111% Y-o-Y. Despite our accelerated growth, it is important to highlight the size of the market opportunity across the Brazilian financial system. The total revenue pool across the Brazilian financial system represents over R$770 billion, which today equates to almost 90 times the size of XP Inc.’s revenue. Our existing footprint currently addresses roughly 20% of total financial revenue in Brazil. Our plans include TAM expansion throughout our journey, always focused on maintaining our asset-light business model and leveraging the evolution of the capital markets as a lever for growth.

As we have always done throughout our history, we have grown our company by connecting dots and picking low-hanging fruits, with a focus on profitability, execution and the experience of our clients, adding new businesses gradually and consistently. It is always important to remember that back in 2008 we were a brokerage firm that offered only one product (stocks) for only one customer profile (individuals). Since then, we have built a dynamic ecosystem in terms of products and experiences encompassing multiple agents. We remain in the early stages of our journey, and we believe the growth we have achieved so far will be surpassed by what is yet to come.

Finally, I would like to thank all market participants for the partnership and interactions throughout our first year as a listed company and reinforce my commitment and that of my partners to drive long-term value for shareholders. We are more motivated and energized than ever to build a legacy, inspire our country and contribute to the development of the Brazilian financial system across verticals.

Guilherme Benchimol, CEO

Highlights

4Q20 KPIs

  • TOTAL AUC: R$660 Billion (+61% YoY)
  • ACTIVE CLIENTS: 2.8 million (+63% YoY)
  • NPS: 71
  • GROSS REVENUE: R$2.6 Billion (+41% YoY)
  • ADJUSTED EBITDA: R$891 Million (+42% YoY)
  • ADJUSTED NET INCOME: R$721 Million (+73% YoY)

2020 KPIs

  • GROSS REVENUE: R$8.7 Billion (+58% YoY)
  • ADJUSTED EBITDA: R$2.9 Billion (35.8% Margin)
  • ADJUSTED NET INCOME: R$2.3 Billion (27.8% Margin)

Key Business Metrics

   

4Q20

 

4Q19

 

YoY

 

3Q20

 

QoQ

 

FY20

 

FY19

 

YoY

Operating and Financial Metrics (unaudited)  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

AUC (in R$ bn)  

660

 

409

 

61%

 

563

 

17%

 

660

 

409

 

61%

Active clients (in ‘000s)  

2,777

 

1,702

 

63%

 

2,645

 

5%

 

2,777

 

1,702

 

63%

Retail – gross total revenues (in R$ mn)  

1,844

 

1,155

 

60%

 

1,698

 

9%

 

6,271

 

3,676

 

71%

Institutional – gross total revenues (in R$ mn)  

307

 

306

 

0%

 

239

 

28%

 

1,210

 

802

 

51%

Issuer Services – gross total revenues (in R$ mn)  

323

 

221

 

46%

 

169

 

91%

 

688

 

507

 

36%

Digital Content – gross total revenues (in R$ mn)  

25

 

30

 

-15%

 

32

 

-20%

 

130

 

112

 

16%

Other – gross total revenues (in R$ mn)  

71

 

111

 

-36%

 

107

 

-34%

 

413

 

420

 

-2%

Company Financial Metrics  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross revenue (in R$ mn)  

2,570

 

1,823

 

41%

 

2,245

 

14%

 

8,711

 

5,518

 

58%

Net Revenue (in R$ mn)  

2,395

 

1,691

 

42%

 

2,101

 

14%

 

8,152

 

5,128

 

59%

Gross Profit (in R$ mn)  

1,559

 

1,204

 

29%

 

1,395

 

12%

 

5,451

 

3,522

 

55%

Gross Margin  

65.1%

 

71.2%

 

-612 bps

 

66.4%

 

-132 bps

 

66.9%

 

68.7%

 

-181 bps

Adjusted EBITDA1 (in R$ mn)  

891

 

627

 

42%

 

727

 

23%

 

2,918

 

1,679

 

74%

Adjusted EBITDA margin  

37.2%

 

37.1%

 

11 bps

 

34.6%

 

258 bps

 

35.8%

 

32.7%

 

305 bps

Adjusted Net Income1 (in R$ mn)  

721

 

417

 

73%

 

570

 

26%

 

2,270

 

1,074

 

111%

Adjusted Net Margin  

30.1%

 

24.6%

 

544 bps

 

27.1%

 

294 bps

 

27.8%

 

20.9%

 

691 bps

 

¹ See appendix for a reconciliation of Adjusted Net Income and Adjusted EBITDA.

Operational Performance

Assets Under Custody (in R$ billions)

Total AUC reached R$660 billion on December 31, up 61% year-over-year and 17% quarter-over-quarter. Year-over-year growth was driven by R$198 billion of net inflows and R$53 billion of market appreciation. Despite last year’s uncertainty and market volatility, XP delivered solid AUC growth, while continuing to strengthen brand recognition among Brazilian investors.

Net Inflows (in R$ billions)

Adjusted Net Inflow totaled R$37 billion in 4Q20, stable relative to 3Q20. The average monthly Net Inflow, adjusted for extraordinary equity inflows/outflows, was R$12.7 billion in 2H20, up17% from R$10.8 billion in 1H20. For 4Q20, flows were strong across all channels and brands, led by the Private segment reflecting ongoing cross-selling opportunities across XP’s ecosystem.

Active Clients (in 000’s)

Active clients grew 63% and 5% in 4Q20 vs 4Q19 and 3Q20, respectively. In 2020, client growth was strong across channels, with XP Direct outpacing the IFA channel, and Rico accelerating in 4Q20 following the elimination of brokerage fees in September.

Retail Equity DARTs¹ (million trades)

¹Daily Average Revenue Trades, including Stocks, REITs, Options and Futures

Retail DARTs have held strong since 2Q20 with 2.6 million daily average trades in 4Q20 despite a typical seasonal slowdown in December due to the holiday season. Retail DARTs at Rico reached a record level in 4Q20 following the implementation of zero brokerage fees in September.

Collateralized Credit Portfolio (in R$ millions)

Our Credit portfolio reached R$3.9 billion of assets as of December 31, 2020, which represented 0.6% of our total AUC. Demand was driven by both individuals and SMB clients, boosted by XP’s AUC growth and the Government’s decision to charge zero IOF (Tax on Financial Operations) on loans granted over the last two weeks of the year.

The average duration of our credit book was 3.2 years, with a 90-day Non-Performing Loan (NPL) ratio of 0.0% at year-end. Furthermore, we highlight the asset-light nature of our loan book, which currently represents R$721 million of Risk-Weighted Assets and requires minimum regulatory capital of just R$58 million.

The fact that most of our credit portfolio is collateralized minimizes capital needs for growth. Our book is mainly funded by the issuance of Structured Notes (COEs) and Deposits, which are distributed to clients on our platform.

Net Promoter Score (NPS)

Our NPS, a widely known survey methodology used to measure customer satisfaction, increased to 71 in December 2020. Maintaining a high NPS score is a priority for XP since our business model is built around the client experience. The NPS calculation as of a given date reflects the average scores in the prior six months.

Total Gross Revenue (in R$ millions)

Total Gross Revenue increased 41% from R$1.8 billion in 4Q19 to R$2.6 billion in 4Q20. For the year, gross revenue expanded 58% to R$8.7 billion in 2020 from R$5.5 billion in 2019. The increase was mainly driven by strong growth in the Retail business, which contributed 92% and 81% of the growth in 4Q20 and 2020, respectively.

Retail

Retail Revenue (in R$ millions)

4Q20 vs 4Q19

Retail revenue grew 60% from R$1.2 billion in 4Q19 to R$1.8 billion in 4Q20. The main growth drivers included, in order of contribution: (1) Equities and Futures, reflecting resilient trading volumes and growing participation of retail investors at B3; (2) Financial Products, represented by Structured Notes (COE) and equity-linked derivatives; and (3) Fixed Income.

In 4Q20, Retail-related revenues represented 75% of consolidated Net Income from Financial Instruments, as per the Accounting Income Statement, and were composed of Derivatives with Retail Clients, Fixed Income secondary transactions, and Floating, among others.

2020 vs 2019

Retail revenue totaled R$6.3 billion in 2020, a 71% increase compared to 2019, and contributing 81% of total revenue growth, mainly driven by platform growth, both in AUC and Active Clients. For 2020, Equities and Futures, Financial Products, and Fixed Income were also the main growth drivers, in order of contribution.

LTM Take Rate (LTM Retail Revenue / Average AUC)

4Q20 take rate (for the last twelve months) remained stable compared to 4Q19. Despite the strong growth in AUC during the period, higher Equities and Futures’ trading volumes and rising distribution of Financial Products and securities through Capital Markets worked as an offset.

Note: LTM Take Rate (LTM Retail Revenue / Average AUC). Average AUC = (Sum of AUC from beginning of period and each quarter end in a given year, being 5 data points in one year)/5

Institutional

Institutional Revenue (in R$ millions)

4Q20 vs 4Q19

Institutional gross revenue remained stable in 4Q20, since 4Q19 had strong performance fees from funds, which offset a higher equity trading volume in 4Q20.

In 4Q20, Institutional revenue accounted for 16% of consolidated Net Income from Financial Instruments, as per the Accounting Income Statement, and was composed mostly of Fixed Income secondary transactions and Derivatives, among others.

2020 vs 2019

Compared to 2019, Institutional revenue grew 51%, from R$802 million to R$1.2 billion, driven by market activity benefiting both fixed income and equity trading volume.

Issuer Services

Issuer Services Revenue (in R$ millions)

4Q20 vs 4Q19

Issuer Services revenue expanded 46% year-over-year from R$221 million in 4Q19 to R$323 million in 4Q20. This increase was driven by (1) Equity Capital Markets (ECM), with 11 executed deals vs 8 in 4Q19, and (2) our Debt Capital Markets (DCM) division, with participation in 55 deals vs 51 in 4Q19.

2020 vs 2019

Issuer Services revenue grew 36% year-over-year, from R$507 million in 2019 to R$688 million in 2020, despite modest activity in 2Q20 due to overall market conditions. The increase was mainly attributable to (1) Equity Capital Markets (ECM), with 32 executed deals vs 13 in 2019 and (2) and Debt Capital Markets (DCM) division, with 147 deals vs 145 in 2019.

In 2020, XP Investment Banking was a protagonist in capital markets, ranked #1 in the distribution of (1) Fixed Income & Hybrid products (consolidated), (2) REITs distribution, and (3) in CRA (agribusiness certificate of receivable), participating in 25%, 56%, and 46% of total deals, respectively.

Digital Content and Other

Digital Content Revenue

Gross revenue totaled R$25 million in 4Q20, down 15% from R$30 million in 4Q19. When looking at full-year figures, Digital content had a solid year, growing revenues 16% over 2019. 4Q20 was impacted mostly by the absence of in-person events and courses compared to the same period of last year.

Other Revenue

4Q20 vs 4Q19

Other revenue decreased 36% in 4Q20 vs. 4Q19, from R$111 million to R$71 million, primarily driven by a lower average Selic rate.

In 4Q20, other revenue accounted for 9% of consolidated Net Income from Financial Instruments, as per the Accounting Income Statement, composed mostly of interest on adjusted gross cash and a small portion related to our treasury’s asset liability management.

2020 vs 2019

Other revenue remained stable for the full-year comparison, impacted by a lower average Selic rate, offset by an increase in the average adjusted gross cash balance during the year.

COGS

COGS (in R$ millions) and Gross Margin

4Q20 vs 4Q19

COGS rose 72% from R$487 million in 4Q19 to R$836 million in 4Q20, reducing gross margin from 71.2% to 65.1%, driven by an (i) 306 bps compression caused by long-term incentive plans to our IFAs, from which 182 bps are related to share-based compensation; and (ii) 259 bps from product mix.

2020 vs 2019

For the year, COGS rose 68%, from R$1.6 billion to R$2.7 billion, driven by the increase in revenues from our IFA Network and active clients. Gross profit margin decreased 181 bps, also affected by the investments made in the IFA network in the second half of 2020.

SG&A Expenses

SG&A Expense (ex-Share-Based Compensation) (in R$ millions)

4Q20 vs 4Q19

SG&A expenses (excluding share-based compensation) totaled R$717 million in 4Q20, up 20% from R$599 million in 4Q19. Expenses, as a percentage of net revenue, decreased, even though we are significantly growing our headcount (over 50% year-over-year) and being consistently developing our product offering and client experience to address an even greater addressable market. The efficiency gain in SG&A was allowed by past investments in technology and our highly scalable platform business model.

2020 vs 2019

SG&A expenses (excluding share-based compensation) for the full-year of 2020 totaled R$2.6 billion, an increase of 44% over R$1.8 billion from 2019. The efficiency gain, as mentioned above, is mostly related to our highly scalable business model, even considering investments to jump into a greater addressable market.

Share-Based Compensation (in R$ millions)

In December 2019, we implemented our new partnership model, according to which existing or new partners may be entitled to share-based compensation based on cultural fit and individual performance, consisting of restricted stock units and performance share units. Expenses related to this model were significantly higher in 2020. As of December 2020, there was a total of 13,899,648 outstanding shares, or approximately 50% of the total dilution planned and approved during IPO, on December 19.

In 2020, we have anticipated a significant part of the approved dilution, and, for this reason, this increase should not be repeated at the same pace in new grants. We expect to use the approved dilution as originally planned: within five years counting from IPO. A portion of Share-Based Compensation is related to IFAs and allocated in COGS.

Adjusted EBITDA

Adjusted EBITDA¹ (in R$ millions) and Margin

¹ See appendix for a reconciliation of Adjusted EBITDA.

4Q20 vs 4Q19

Adjusted EBITDA grew 42%, from R$627 million to R$891 million. The growth was driven by (1) strong growth in Retail Revenue and (2) operating leverage in SG&A. Both were partially offset by higher COGS, impacted by investments made in our IFA Network.

2020 vs 2019

Compared to 2019, Adjusted EBITDA expanded 74%, from R$1.7 billion to R$2.9 billion. Despite (1) growing our number of employees 50% year-over-year, (2) investing in new business (such as credit cards and digital bank), and (3) investing in our IFA Network, adjusted EBITDA Margin expanded from 32.7% to 35.8%. The margin expansion reflects the benefits of our operating leverage and technology investments made in the past, which provided scalability for the company.

Adjusted Net Income

Adjusted Net Income¹ (in R$ millions) and Margin

4Q20 vs 4Q19

Adjusted Net Income grew 73%, from R$417 million to R$721 million, driven by (1) strong performance of the Retail business and (2) a lower effective tax rate, as a result of our post-IPO corporate structure. Our adjusted net income margin expanded by 544 bps in 4Q20.

2020 vs 2019

In 2020, Adjusted Net Income grew 111% vs 2019 and reached R$2.3 billion. The adjusted net margin expanded from 20.9% in 2019 to 27.8% in 2020, up 691 bps, reflecting: (1) strong growth in Retail Revenue, which was mainly driven by Equity, Derivatives, Financial Products and Fixed Income, (2) a lower effective tax rate; and (3) operating leverage in SG&A.

¹ See appendix for a reconciliation of Adjusted Net Income.

Guidance

We have revised our 3-5 year adjusted net margin guidance, from previous 18-22% range to 24-30%.

Cash flow (in R$ millions)

   

4Q20

 

3Q20

  FY20   FY19
Cash Flow Data                
Income before income tax   

663

 

632

 

2,421

 

1,544

Adjustments to reconcile income before income tax   

229

 

128

 

564

 

206

Income tax paid  

(97)

 

(126)

 

(519)

 

(403)

Contingencies paid  

(1)

 

(0)

 

(2)

 

(3)

Interest paid  

(9)

 

(44)

 

(71)

 

(28)

Changes in working capital assets and liabilities   

830

 

(720)

 

565

 

122

Adjusted net cash flow (used in) from operating activities   

1,615

 

(129)

 

2,959

 

1,437

Net cash flow (used in) from securities, repos, derivatives and banking activities  

(959)

 

1,119

 

(1,448)

 

(5,251)

Net cash flows from operating activities   

656

 

990

 

1,511

 

(3,814)

Net cash flows from investing activities   

(202)

 

(302)

 

(582)

 

(161)

Net cash flows from financing activities   

1,390

 

(478)

 

789

 

4,234

Net Cash Flow Used in Operating Activities

Our net cash flow used in Operating activities represented by Adjusted net cash flow (used in) from operating activities (which in management’s view is a more useful metric to track the intrinsic cash flow generation of the business) increased to R$1.6 billion for 4Q20 from negative R$129 million in 3Q20, and increased from R$1.4 billion in 2019 to R$3.0 billion in 2020 driven by:

  • Higher balance of securities and derivatives that we hold in the ordinary course of our business as a Retail investment distribution platform and as an Institutional broker-dealer (concerning the sale of fixed income securities and structured notes);
  • Our strategy to allocate excess cash and cash equivalents from treasury funds, from Floating Balances and private pension balances to securities and other financial assets. These balances may fluctuate substantially from quarter to quarter and were the key drivers to the net cash flow from operating activities figures;
  • Increases in our banking activities from loan operations, deposits mainly derived from time deposits, structured operations certificates (COE) and other financial liabilities which include financial bills as a result of our expected growth in new financial services verticals.
  • Growth of our omnichannel distribution network through our network of IFA partners;
  • Our income before tax of R$892 million in 4Q20 and R$3.0 billion in 2020 combined with non-cash expenses consisting primarily of (i) share-based plan of R$154 million in 4Q20 and R$233 million in 2020 (ii) depreciation and amortization of R$37 million in 4Q20 and R$143 million in 2020, (iii) Losses on impairment and write-off of property, equipment, intangible assets and leases of R$11 million in 4Q20 and R$73 million in 2020. The total amount of adjustments to reconcile income before income taxes for 4Q20 was R$229 million and R$564 million for 2020.

Net Cash Flow Used in Investing Activities

Our net cash used in investing activities decreased from R$302 million in 3Q20 to R$202 million in 4Q20 and increased from R$161 million in 2019 to R$582 million in 2020, primarily affected by:

  • Our acquisitions of FinTech’s investments in associates and joint ventures of R$290 million in 2020;
  • the investment in intangible assets, mostly IT infrastructure and capitalized software development which increased from R$35 million in 3Q20 to R$66 million in 4Q20 and from R$89 million in 2019 to R$145 million in 2020.

Net Cash Provided by Financing Activities

Our net cash flows from financing activities increased from negative R$478 million in 3Q20 to R$1.4 billion in 4Q20 and decreased from R$4.2 billion in 2019 to R$789 million in 2020, primarily due to:

  • R$1.4 billion related to proceeds from the issuance of shares related to our primary offering in 4Q20;
  • R$400 million related to principal payments of the first series of non-convertible debentures in 3Q20;
  • R$66 million related to a partial repurchase of the second series of non-convertible debentures in 2Q20;
  • R$4.5 billion related to the initial public offering proceeds in 2019 and;
  • R$22 million in 4Q20, R$78 million in 3Q20, R$153 million in 2020 and R$123 million in 2019 related to Payments of borrowings and lease liabilities.

Floating Balance and Adjusted Gross Financial Assets (in R$ millions)

Floating Balance (=net uninvested clients’ deposits)  

4Q20

 

3Q20

Assets  

(1,052)

 

(1,484)

(-) Securities trading and intermediation    

(1,052)

 

(1,484)

Liabilities  

20,303

 

15,160

(+) Securities trading and intermediation    

20,303

 

15,160

(=) Floating Balance  

19,252

 

13,676

Adjusted Gross Financial Assets  

4Q20

 

3Q20

Assets  

90,518

 

83,061

(+) Cash  

1,955

 

642

(+) Securities – Fair value through profit or loss  

49,590

 

38,702

(+) Securities – Fair value through other comprehensive income  

19,039

 

9,589

(+) Securities – Evaluated at amortized cost  

1,829

 

1,366

(+) Derivative financial instruments  

7,559

 

13,149

(+) Securities purchased under agreements to resell  

6,627

 

18,244

(+) Loans  

3,918

 

1,369

Liabilities  

(60,484)

 

(61,514)

(-) Securities loaned  

(2,237)

 

(1,112)

(-) Derivative financial instruments  

(7,819)

 

(12,730)

(-) Securities sold under repurchase agreements  

(31,839)

 

(35,254)

(-) Private Pension Liabilities  

(13,388)

 

(9,649)

(-) Deposits  

(3,022)

 

(1,627)

(-) Structured Operations  

(2,178)

 

(1,142)

(-) Floating Balance  

(19,252)

 

(13,676)

(=) Adjusted Gross Financial Assets  

10,782

 

7,871

We present Adjusted Gross Financial Assets because we believe this metric captures the liquidity that is, in fact, available to us, net of the portion of liquidity that is related to our Floating Balance (and therefore attributable to clients). We calculate Adjusted Gross Financial Assets as the sum of (1) Cash and Financial Assets (comprised of Cash plus Securities – Fair value through profit or loss, plus Securities – Fair value through other comprehensive income, plus Securities – Evaluated at amortized cost, plus Derivative financial instruments, plus Securities (purchased under agreements to resell), plus Loans, less (2) Financial Liabilities (comprised of the sum of Securities loaned, Derivative financial instruments, Securities sold under repurchase agreements and Private pension liabilities), Deposits, Structured Operation Certificates (COE) and (3) less Floating Balance.

It is a measure that we track internally daily, and it more intuitively reflects the effect of the operational profits we generate and the variations between working capital assets and liabilities (cash flows from operating activities), investments in fixed and intangible assets (cash flows from investing activities) and inflows and outflows related to equity and debt securities in our capital structure (cash flows from financing activities).

Our management treats all securities and financial instrument assets, net of financial instrument liabilities, as balances that compose our total liquidity, with subline items (such as, for example, “securities at fair value through profit and loss” and “securities at fair value through other comprehensive income”) expected to fluctuate substantially from quarter to quarter as our treasury manages and allocates our total liquidity to the most suitable financial instruments.

Other Information

Web Meeting

The Company will host a webcast to discuss its 4Q20 financial results on Tuesday, February 23, 2021, at 5:00 pm ET (7:00 pm BRT). To participate in the earnings webcast please subscribe at 4Q20 Earnings Web Meeting. The replay will be available on XP’s investor relations website at https://investors.xpinc.com/.

Important Disclosure

IN REVIEWING THE INFORMATION CONTAINED IN THIS RELEASE, YOU ARE AGREEING TO ABIDE BY THE TERMS OF THIS DISCLAIMER. THIS INFORMATION IS BEING MADE AVAILABLE TO EACH RECIPIENT SOLELY FOR ITS INFORMATION AND IS SUBJECT TO AMENDMENT.

This release is prepared by XP Inc. (the “Company,” “we” or “our”), is solely for informational purposes. This release does not constitute a prospectus and does not constitute an offer to sell or the solicitation of an offer to buy any securities. In addition, this document and any materials distributed in connection with this release are not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction.

This release was prepared by the Company. Neither the Company nor any of its affiliates, officers, employees or agents, make any representation or warranty, express or implied, in relation to the fairness, reasonableness, adequacy, accuracy or completeness of the information, statements or opinions, whichever their source, contained in this release or any oral information provided in connection herewith, or any data it generates and accept no responsibility, obligation or liability (whether direct or indirect, in contract, tort or otherwise) in relation to any of such information. The information and opinions contained in this release are provided as at the date of this release, are subject to change without notice and do not purport to contain all information that may be required to evaluate the Company. The information in this release is in draft form and has not been independently verified. The Company and its affiliates, officers, employees and agents expressly disclaim any and all liability which may be based on this release and any errors therein or omissions therefrom. Neither the Company nor any of its affiliates, officers, employees or agents makes any representation or warranty, express or implied, as to the achievement or reasonableness of future projections, management targets, estimates, prospects or returns, if any.

The information contained in this release does not purport to be comprehensive and has not been subject to any independent audit or review. Certain of the financial information as of and for the periods ended December 31, 2019, 2018 and 2017 has been derived from audited financial statements and all other financial information has been derived from unaudited interim financial statements. A significant portion of the information contained in this release is based on estimates or expectations of the Company, and there can be no assurance that these estimates or expectations are or will prove to be accurate. The Company’s internal estimates have not been verified by an external expert, and the Company cannot guarantee that a third party using different methods to assemble, analyze or compute market information and data would obtain or generate the same results.

Statements in the release, including those regarding the possible or assumed future or other performance of the Company or its industry or other trend projections, constitute forward-looking statements. These statements are generally identified by the use of words such as “anticipate,” “believe,” “could,” “expect,” “should,” “plan,” “intend,” “estimate” and “potential,” among others. By their nature, forward-looking statements are necessarily subject to a high degree of uncertainty and involve known and unknown risks, uncertainties, assumptions and other factors because they relate to events and depend on circumstances that will occur in the future whether or not outside the control of the Company. Such factors may cause actual results, performance or developments to differ materially from those expressed or implied by such forward-looking statements and there can be no assurance that such forward-looking statements will prove to be correct. These risks and uncertainties include factors relating to: (1) general economic, financial, political, demographic and business conditions in Brazil, as well as any other countries we may serve in the future and their impact on our business; (2) fluctuations in interest, inflation and exchange rates in Brazil and any other countries we may serve in the future; (3) competition in the financial services industry; (4) our ability to implement our business strategy; (5) our ability to adapt to the rapid pace of technological changes in the financial services industry; (6) the reliability, performance, functionality and quality of our products and services and the investment performance of investment funds managed by third parties or by our asset managers; (7) the availability of government authorizations on terms and conditions and within periods acceptable to us; (8) our ability to continue attracting and retaining new appropriately-skilled employees; (9) our capitalization and level of indebtedness; (10) the interests of our controlling shareholders; (11) changes in government regulations applicable to the financial services industry in Brazil and elsewhere; (12) our ability to compete and conduct our business in the future; (13) the success of operating initiatives, including advertising and promotional efforts and new product, service and concept development by us and our competitors; (14) changes in consumer demands regarding financial products, customer experience related to investments and technological advances, and our ability to innovate to respond to such changes; (15) changes in labor, distribution and other operating costs; (16) our compliance with, and changes to, government laws, regulations and tax matters that currently apply to us; (17) other factors that may affect our financial condition, liquidity and results of operations. Accordingly, you should not place undue reliance on forward-looking statements. The forward-looking statements included herein speak only as at the date of this release and the Company does not undertake any obligation to update these forward-looking statements. Past performance does not guarantee or predict future performance. Moreover, the Company and its affiliates, officers, employees and agents do not undertake any obligation to review, update or confirm expectations or estimates or to release any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of the release. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented and we do not intend to update any of these forward-looking statements.

Market data and industry information used throughout this release are based on management’s knowledge of the industry and the good faith estimates of management. The Company also relied, to the extent available, upon management’s review of industry surveys and publications and other publicly available information prepared by a number of third-party sources. All of the market data and industry information used in this release involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. Although the Company believes that these sources are reliable, there can be no assurance as to the accuracy or completeness of this information, and the Company has not independently verified this information.

The contents hereof should not be construed as investment, legal, tax or other advice and you should consult your own advisers as to legal, business, tax and other related matters concerning an investment in the Company. The Company is not acting on your behalf and does not regard you as a customer or a client. It will not be responsible to you for providing protections afforded to clients or for advising you on the relevant transaction.

This release includes our Floating Balance, Adjusted Gross Financial Assets, Adjusted EBITDA and Adjustments to Reported Net Income, which are non-GAAP financial information. We believe that such information is meaningful and useful in understanding the activities and business metrics of the Company’s operations. We also believe that these non-GAAP financial measures reflect an additional way of viewing aspects of the Company’s business that, when viewed with our International Financial Reporting Standards (“IFRS”) results, as issued by the International Accounting Standards Board, provide a more complete understanding of factors and trends affecting the Company’s business. Further, investors regularly rely on non-GAAP financial measures to assess operating performance and such measures may highlight trends in the Company’s business that may not otherwise be apparent when relying on financial measures calculated in accordance with IFRS. We also believe that certain non-GAAP financial measures are frequently used by securities analysts, investors and other interested parties in the evaluation of public companies in the Company’s industry, many of which present these measures when reporting their results. The non-GAAP financial information is presented for informational purposes and to enhance understanding of the IFRS financial statements. The non-GAAP measures should be considered in addition to results prepared in accordance with IFRS, but not as a substitute for, or superior to, IFRS results. As other companies may determine or calculate this non-GAAP financial information differently, the usefulness of these measures for comparative purposes is limited. A reconciliation of such non-GAAP financial measures to the nearest GAAP measure is included in this release.

For purposes of this release:

“Active Clients” means the total number of retail clients served through our XP Investimentos, Rico, Clear, XP Investments and XP Private (Europe) brands, with an AUC above R$100.00 or that have transacted at least once in the last thirty days. For purposes of calculating this metric, if a client holds an account in more than one of the aforementioned entities, such client will be counted as one “active client” for each such account. For example, if a client holds an account in each of XP Investimentos and Rico, such client will count as two “active clients” for purposes of this metric.

“Assets Under Custody (AUC)” means the market value of all client assets invested through XP’s platform and that is related to reported Retail Revenue, including equities, fixed income securities, mutual funds (including those managed by XP Gestão de Recursos Ltda., XP Advisory Gestão de Recursos Ltda. and XP Vista Asset Management Ltda., as well as by third-party asset managers), pension funds (including those from XP Vida e Previdência S.A., as well as by third-party insurance companies), exchange traded funds, COEs (Structured Notes), REITs, and uninvested cash balances (Floating Balances), among others. Although AUC includes custody from Corporate Clients that generate Retail Revenue, it does not include custody from institutional clients (asset managers, pension funds and insurance companies).

Rounding

We have made rounding adjustments to some of the figures included in this annual report. Accordingly, numerical figures shown as totals in some tables may not be an arithmetic aggregation of the figures that preceded them.

Unaudited Managerial Income Statement (in R$ millions)

   

4Q20

 

4Q19

 

YoY

 

3Q20

 

QoQ

 

FY20

 

FY19

 

YoY

Managerial Income Statement  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Gross Revenue  

2,570

 

1,823

 

41%

 

2,245

 

14%

 

8,711

 

5,518

 

58%

Retail  

1,844

 

1,155

 

60%

 

1,698

 

9%

 

6,271

 

3,676

 

71%

Institutional  

307

 

306

 

0%

 

239

 

28%

 

1,210

 

802

 

51%

Issuer Services  

323

 

221

 

46%

 

169

 

91%

 

688

 

507

 

36%

Digital Content  

25

 

30

 

-15%

 

32

 

-20%

 

130

 

112

 

16%

Other  

71

 

111

 

-36%

 

107

 

-34%

 

413

 

420

 

-2%

Net Revenue  

2,395

 

1,691

 

42%

 

2,101

 

14%

 

8,152

 

5,128

 

59%

COGS  

(836)

 

(487)

 

72%

 

(706)

 

18%

 

(2,701)

 

(1,606)

 

68%

As a % of Net Revenue  

(34.9%)

 

(28.8%)

 

-6.1 p.p

 

(33.6%)

 

-1.3 p.p

 

(33.1%)

 

(31.3%)

 

-1.8 p.p

Gross Profit  

1,559

 

1,204

 

29%

 

1,395

 

12%

 

5,451

 

3,522

 

55%

Gross Margin  

65.1%

 

71.2%

 

-6.1 p.p

 

66.4%

 

-1.3 p.p

 

66.9%

 

68.7%

 

-1.8 p.p

SG&A  

(717)

 

(599)

 

20%

 

(669)

 

7%

 

(2,584)

 

(1,794)

 

44%

Share Based Compensation1  

(136)

 

(8)

 

1714%

 

(44)

 

207%

 

(250)

 

(8)

 

3225%

EBITDA  

705

 

598

 

18%

 

681

 

4%

 

2,616

 

1,720

 

52%

EBITDA Margin  

29.4%

 

35.3%

 

-5.9 p.p

 

32.4%

 

-3.0 p.p

 

32.1%

 

33.5%

 

-1.4 p.p

Adjusted EBITDA  

891

 

627

 

42%

 

727

 

23%

 

2,918

 

1,679

 

74%

Adjusted EBITDA Margin  

37.2%

 

37.1%

 

0.1 p.p

 

34.6%

 

2.6 p.p

 

35.8%

 

32.7%

 

3.0 p.p

D&A  

(37)

 

(29)

 

30%

 

(36)

 

3%

 

(143)

 

(92)

 

56%

EBIT  

668

 

569

 

17%

 

645

 

4%

 

2,473

 

1,629

 

52%

Interest expense on debt  

(6)

 

(22)

 

-71%

 

(12)

 

-46%

 

(53)

 

(84)

 

-38%

Share of profit or (loss) in joint ventures and associates  

1

 

 

n.a.

 

(1)

 

n.a.

 

1

 

 

n.a.

EBT  

663

 

547

 

21%

 

632

 

5%

 

2,421

 

1,544

 

57%

Income tax expense  

(60)

 

(157)

 

-61%

 

(91)

 

-34%

 

(340)

 

(455)

 

-25%

Effective Tax Rate  

(9.1%)

 

(28.7%)

 

19.5 p.p

 

(14.4%)

 

5.3 p.p

 

(14.0%)

 

(29.4%)

 

15.4 p.p

Net Income  

602

 

390

 

54%

 

541

 

11%

 

2,081

 

1,089

 

91%

Net Margin  

25.2%

 

23.1%

 

2.1 p.p

 

 25.8%

 

-0.6 p.p

 

25.5%

 

21.2%

 

4.3 p.p

Non Recurring Items  

118

 

27

 

343%

 

29

 

309%

 

189

 

(16)

 

-1305%

Adjusted Net Income  

721

 

417

 

73%

 

570

 

26%

 

2,270

 

1,074

 

111%

Adjusted Net Margin  

 30.1%

 

 24.6%

 

5.4 p.p

 

 27.1%

 

2.9 p.p

 

 27.8%

 

 20.9%

 

6.91 p.p

 

¹ A portion of total Share-Based Compensation is related to IFAs and allocated in COGS

Accounting Income Statement (in R$ millions)

   

4Q20

 

4Q19

 

YoY

 

3Q20

 

QoQ

 

FY20

 

FY19

 

YoY

Accounting Income Statement  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net revenue from services rendered  

1,523

 

1,255

 

21%

 

1,278

 

19%

 

5,016

 

3,596

 

40%

Brokerage commission  

545

 

352

 

55%

 

548

 

-1%

 

2,140

 

1,288

 

66%

Securities placement  

508

 

462

 

10%

 

388

 

31%

 

1,430

 

1,155

 

24%

Management fees  

415

 

444

 

-6%

 

274

 

51%

 

1,224

 

1,035

 

18%

Insurance brokerage fee  

39

 

37

 

4%

 

18

 

118%

 

113

 

106

 

6%

Educational services  

23

 

23

 

-1%

 

25

 

-11%

 

118

 

98

 

21%

Other services  

143

 

63

 

129%

 

155

 

-8%

 

478

 

275

 

73%

Taxes and contributions on services  

(148)

 

(125)

 

18%

 

(131)

 

13%

 

(486)

 

(362)

 

34%

Net income from financial instruments at amortized cost and at fair value through other comprehensive income  

(115)

 

(4)

 

n.a.

 

190

 

n.a.

 

188

 

200

 

-6%

Net income from financial instruments at fair value through profit or loss  

987

 

441

 

124%

 

633

 

56%

 

2,947

 

1,332

 

121%

Total revenue and income  

2,395

 

1,691

 

42%

 

2,101

 

14%

 

8,152

 

5,128

 

59%

Expected credit losses  

(17)

 

(3)

 

463%

 

(10)

 

82%

 

(56)

 

(9)

 

490%

Operating costs  

(819)

 

(484)

 

69%

 

(696)

 

18%

 

(2,645)

 

(1,597)

 

66%

Selling expenses  

(41)

 

(73)

 

-44%

 

(38)

 

6%

 

(135)

 

(155)

 

-13%

Administrative expenses  

(936)

 

(597)

 

57%

 

(810)

 

16%

 

(3,014)

 

(1,891)

 

59%

Other operating revenues (expenses), net  

86

 

35

 

146%

 

98

 

-12%

 

171

 

153

 

12%

Interest expense on debt  

(6)

 

(22)

 

-71%

 

(12)

 

-46%

 

(53)

 

(84)

 

-38%

Share of profit or (loss) in joint ventures and associates  

1

 

 

n.a.

 

(1)

 

n.a.

 

1

 

 

n.a.

Income before income tax  

663

 

547

 

21%

 

632

 

5%

 

2,421

 

1,544

 

57%

Income tax expense  

(60)

 

(157)

 

-61%

 

(91)

 

-34%

 

(340)

 

(455)

 

-25%

Effective tax rate  

(9.1%)

 

(28.7%)

 

19.6 p.p

 

(14.4%)

 

5.3 p.p

 

(14.0%)

 

(29.4%)

 

15.4 p.p

Net income for the period  

602

 

390

 

54%

 

541

 

11%

 

2,081

 

1,089

 

91%

Balance Sheet (in R$ millions)

   

2020

 

2019

Assets  

 

 

 

Cash  

1,955

 

110

Financial assets  

90,191

 

41,889

Fair value through profit or loss  

57,149

 

26,528

Securities  

49,590

 

22,443

Derivative financial instruments  

7,559

 

4,085

Fair value through other comprehensive income  

19,039

 

2,616

Securities  

19,039

 

2,616

Evaluated at amortized cost  

14,002

 

12,744

Securities  

1,829

 

2,267

Securities purchased under agreements to resell   

6,627

 

9,490

Securities trading and intermediation   

1,052

 

505

Accounts receivable  

506

 

462

Loan Operations  

3,918

 

0

Other financial assets   

70

 

20

Other assets  

1,761

 

644

Recoverable taxes  

128

 

243

Rights-of-use assets  

183

 

227

Prepaid expenses  

1,394

 

90

Other   

57

 

83

Deferred tax assets  

505

 

285

Investments in associates and joint ventures  

700

 

Property and equipment   

204

 

142

Intangible assets  

714

 

553

Total Assets  

96,029

 

43,623

 

 

 

 

   

2020

 

2019

Liabilities  

 

 

 

Financial liabilities  

70,601

 

31,842

Fair value through profit or loss  

10,057

 

5,251

Securities  

2,237

 

2,022

Derivative financial instruments  

7,819

 

3,229

Evaluated at amortized cost  

60,544

 

26,591

Securities sold under repurchase agreements  

31,839

 

15,638

Securities trading and intermediation    

20,303

 

9,115

Deposits  

3,022

 

70

Structured operations certificates  

2,178

 

19

Accounts payables  

860

 

267

Borrowings and lease liabilities  

493

 

637

Debentures  

335

 

835

Other financial liabilities  

1,514

 

9

Other liabilities  

14,522

 

4,620

Social and statutory obligations  

667

 

493

Taxes and social security obligations    

436

 

345

Private pension liabilities  

13,388

 

3,759

Provisions and contingent liabilities  

20

 

15

Other  

11

 

7

Deferred tax liabilities  

8

 

5

Total Liabilities  

85,132

 

36,467

Equity attributable to owners of the Parent company  

10,895

 

7,153

Issued capital  

0

 

0

Capital reserve  

10,664

 

6,943

Other comprehensive income  

231

 

210

Retained earnings  

 

Non-controlling interest  

3

 

3

Total equity  

10,898

 

7,156

Total liabilities and equity  

96,029

 

43,623

Adjusted EBITDA (in R$ millions)

   

4Q20

 

4Q19

 

YoY

 

3Q20

 

QoQ

 

FY20

 

FY19

 

YoY

EBITDA  

705

 

598

 

18%

 

681

 

4%

 

2,616

 

1,720

 

52%

(+) Stock Based Compensation  

180

 

8

 

n.a.

 

44

 

305%

 

293

 

8

 

n.a.

(+) Offering expenses  

6

 

22

 

-73%

 

2

 

216%

 

8

 

22

 

-65%

(-) Tax claim recognition (2010-2020)  

 

 

n.a.

 

 

n.a.

 

 

(71)

 

-100%

Adj. EBITDA  

891

 

627

 

42%

 

727

 

23%

 

2,918

 

1,679

 

74%

Adjusted Net Income (in R$ millions)

   

4Q20

 

4Q19

 

YoY

 

3Q20

 

QoQ

 

FY20

 

FY19

 

YoY

Net Income  

602

 

390

 

54%

 

541

 

11%

 

2,081

 

1,089

 

91%

(+) Stock Based Compensation  

180

 

8

 

n.a.

 

44

 

305%

 

293

 

8

 

n.a.

(+) Offering expenses  

6

 

22

 

-73%

 

2

 

216%

 

8

 

22

 

-65%

(-) Tax claim recognition (2010-2020)  

 

 

n.a.

 

 

n.a.

 

 

(71)

 

-100%

(+/-) Taxes  

(68)

 

(3)

 

n.a.

 

(18)

 

283%

 

(113)

 

25

 

n.a.

Adj. Net Income  

721

 

417

 

73%

 

570

 

26%

 

2,270

 

1,074

 

111%

 

Investor Relations Team

André Martins

Antonio Guimarães

Natali Pimenta

[email protected]

KEYWORDS: South America Brazil

INDUSTRY KEYWORDS: Software Technology Professional Services Finance

MEDIA:

Upwork Reports Fourth Quarter and Full Year 2020 Financial Results

  • Fourth quarter 2020 revenue grew 32% year-over-year to $106.2 million
    • Marketplace revenue grew 34% to $96.9 million
  • Full year 2020 revenue grew 24% year-over-year to $373.6 million
    • Marketplace revenue grew 26% to $338.2 million
  • Gross margin expanded two percentage points year-over-year to 73% in the fourth quarter and one percentage point to 72% for full year 2020

SANTA CLARA, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) — Upwork Inc. (Nasdaq: UPWK), the world’s largest work marketplace that connects businesses with independent talent, as measured by gross services volume (“GSV”), today announced its fourth quarter and full year 2020 financial results.

“2020 was a watershed year for Upwork. In the fourth quarter, we achieved our highest year-over-year growth since going public,” said Hayden Brown, President and Chief Executive Officer of Upwork. “Nearly a year into the pandemic, organizations are embracing remote work to unleash the potential of a global workforce of independent talent that gives them the agility, skills and efficiency they need. Our results demonstrate that we are optimally positioned to capture the exciting opportunity ahead by serving customers as the world’s work marketplace.”

Fourth Quarter 2020 Financial Results

  • GSV increased by 33% year-over-year to $727.7 million
  • Revenue grew 32% year-over-year to $106.2 million
  • Marketplace revenue grew 34% year-over-year to $96.9 million
  • Marketplace take rate was 13.5%, up from 13.3% a year ago
  • Gross margin expanded two percentage points year-over-year to 73%
  • Net income was $0.9 million, or $0.01 per share, compared to a net loss of $5.5 million, or $(0.05) per share, in the fourth quarter of 2019
  • Non-GAAP net income was $7.8 million, or $0.06 per share, compared to non-GAAP net income of $3.4 million, or $0.03 per share, in the fourth quarter of 2019
  • Adjusted EBITDA, a non-GAAP financial measure, was $9.6 million compared to $3.5 million in the fourth quarter of 2019

Full Year 2020 Financial Results

  • GSV increased by 21% year-over-year to $2.5 billion
  • Revenue grew 24% to $373.6 million
  • Marketplace revenue grew 26% to $338.2 million
  • Marketplace take rate was 13.6%, up from 13.1% a year ago
  • Gross margin expanded one percentage point year-over-year to 72%
  • Net loss was $22.9 million, or $(0.19) per share, compared to a net loss of $16.7 million, or $(0.15) per share, in the prior year
  • Non-GAAP net income was $6.1 million, or $0.05 per share, compared to non-GAAP net income of $5.5 million, or $0.05 per share, for full year 2019
  • Adjusted EBITDA was $14.0 million compared to $7.4 million in the prior year

Note: Reported figures are rounded; unless otherwise noted, comparisons of the fourth quarter of 2020 are to the fourth quarter of 2019 and comparisons for the full year 2020 are to the full year 2019. All financial measures are GAAP unless cited as non-GAAP. Certain operating metrics used here, including “GSV” and “marketplace take rate,” are defined in our most recently filed Quarterly Report on Form 10-Q and will also be set forth in our Annual Report on Form 10-K for the year ended December 31, 2020 when filed.

A reconciliation of GAAP to non-GAAP financial measures has been provided at the end of this press release. An explanation of these measures is also included below under the heading “Non-GAAP Financial Measures.”

Guidance

The guidance we are providing today factors in the expected impacts of the COVID-19 pandemic that are available to us as of today.

As of February 23, 2021, Upwork is providing the following guidance for its first quarter and full year 2021:

For the first quarter of 2021, Upwork expects to report:

  • Revenue in the range of $107 million to $109 million
  • Adjusted EBITDA in the range of $2 million to $3 million
  • Weighted average shares outstanding in the range of 126 million to 128 million

For the full year 2021, Upwork expects to report:

  • Revenue in the range of $460 million to $470 million
  • Adjusted EBITDA in the range of $12 million to $16 million
  • Weighted average shares outstanding in the range of 130 million to 134 million

Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast

Upwork will host a conference call today at 2 p.m. Pacific Time/5 p.m. Eastern Time to discuss the company’s fourth quarter and full year 2020 financial results. An audio webcast archive will be available following the live event for approximately one year at investors.upwork.com. The prepared remarks corresponding to the information reviewed on today’s conference call will also be available on our Investor Relations website, once the call has concluded.

We use our investor relations website (investors.upwork.com), our Twitter handle (twitter.com/Upwork) and Hayden Brown’s Twitter handle (twitter.com/hydnbrwn) and LinkedIn profile (linkedin.com/in/haydenlbrown) as a means of disseminating or providing notification of, among other things, news or announcements regarding our business or financial performance, investor events, press releases and earnings releases and as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. The content of our websites and information that we may post on or provide to online and social media channels, including those mentioned above, and information that can be accessed through our websites or these online and social media channels are not incorporated by reference into this press release or in any report or document we file with the SEC, and any references to our websites or these online and social media channels are intended to be inactive textual references only.

Safe Harbor Statement

This press release includes forward-looking statements, which are statements other than statements of historical facts, and statements in the future tense. These statements include, but are not limited to, statements regarding the future performance of Upwork and its market opportunity, including expected financial results for the first quarter and full year of 2021, expectations regarding the impact of the COVID-19 pandemic on our business and industry, and expectations for capturing market share and regarding the changing landscape of work, as well as statements regarding our planned investments to support growth. Accordingly, actual results could differ materially or such uncertainties could cause adverse effects on our results. Forward-looking statements are based upon various estimates and assumptions, as well as information known to Upwork as of the date of this press release, and are subject to risks and uncertainties, including but not limited to: the impact and duration of the COVID-19 pandemic on our business and global economic conditions; the impact, severity and duration of safety measures put in place to mitigate the impact of the COVID-19 pandemic; our ability to attract and retain a community of freelancers and clients; our limited operating history under our current business strategy and pricing model; our focus on the long-term and our investments in sustainable, profitable growth; our ability to develop and release new products and services, and develop and release successful enhancements, features, and modifications to our existing products and services; the impact of new and existing laws and regulations; our ability to generate revenue from our marketplace offerings and the effects of fluctuations in our level of client spend retention; our ability to develop, maintain, and enhance our brand and reputation cost-effectively; competition; challenges to contractor classification or employment status of freelancers on our work marketplace; the possibility that the market for freelancers and the services they offer will develop more slowly than we expect; user circumvention of our work marketplace; our ability to sell to large enterprise, global account, and mid-market clients; the success of our investments in our enterprise sales organization and our related marketing efforts, and expectations for the ability for enterprise sales to drive incremental revenue and GSV growth; changes in the amount and mix of services facilitated through our work marketplace from period to period; changes in our level of investment in sales and marketing, research and development, and general and administrative expenses, and our hiring plans for sales personnel; the market for information technology; future changes to our pricing model; payment and fraud risks; security breaches; privacy; litigation and related costs; changes in management; and other general market, political, economic, and business conditions. Actual results could differ materially from those predicted or implied, and reported results should not be considered as an indication of future performance. Additionally, these forward-looking statements, particularly our guidance, involve risks, uncertainties and assumptions, including those related to the impacts of the COVID-19 pandemic on our clients’ spending decisions. Significant variation from the assumptions underlying our forward-looking statements could cause our actual results to vary, and the impact could be significant.

Additional risks and uncertainties that could affect our financial results are included under the caption “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our most recent Annual Report on Form 10-K and subsequent quarterly reports on Form 10-Q, which are available on the Investor Relations page of our website at investors.upwork.com and on the SEC website at www.sec.gov. Additional information will also be set forth in our Annual Report on Form 10-K for the year ended December 31, 2020 when filed. All forward-looking statements contained herein are based on information available to us as of the date hereof, and we do not assume any obligation to update these statements as a result of new information or future events.

Undue reliance should not be placed on the forward-looking statements in this press release. These statements are based on information available to Upwork on the date hereof, and Upwork assumes no obligation to update such statements.

Non-GAAP Financial Measures

To supplement our condensed consolidated financial statements, which are prepared in accordance with GAAP, we present non-GAAP cost of revenue (and as a percentage of revenue), non-GAAP gross profit (and as a percentage of revenue), non-GAAP operating expenses (total and each line item, and total and each non-GAAP operating expense item as a percentage of revenue), non-GAAP income (loss) from operations (and as a percentage of revenue), non-GAAP net income (loss) (and as a percentage of revenue and on a per share basis), and adjusted EBITDA in this press release. Our use of non-GAAP financial measures has limitations as an analytical tool, and these measures should not be considered in isolation or as a substitute for analysis of financial results as reported under GAAP.

We use these non-GAAP financial measures in conjunction with financial measures prepared in accordance with GAAP for planning purposes, including in the preparation of our annual operating budget, as a measure of our core operating results and the effectiveness of our business strategy, and in evaluating our financial performance. These measures provide consistency and comparability with past financial performance, facilitate period-to-period comparisons of core operating results, and also facilitate comparisons with other peer companies, many of which use similar non-GAAP financial measures to supplement their GAAP results. In addition, adjusted EBITDA is widely used by investors and securities analysts to measure a company’s operating performance. We exclude the following items from one or more of our non-GAAP financial measures: stock-based compensation expense (non-cash expense calculated by companies using a variety of valuation methodologies and subjective assumptions), depreciation and amortization (non-cash expense), interest expense, other (income) expense, net, income tax (benefit) provision, and, if applicable, other non-cash transactions.

Investors are cautioned that there are material limitations associated with the use of non-GAAP financial measures as an analytical tool. In particular, (1) stock-based compensation expense has recently been, and will continue to be for the foreseeable future, a significant recurring expense for our business and an important part of our compensation strategy, (2) although depreciation and amortization expense are non-cash charges, the assets subject to depreciation and amortization may have to be replaced in the future, and adjusted EBITDA does not reflect cash capital expenditure requirements for such replacements or for new capital expenditure requirements, and (3) adjusted EBITDA does not reflect: (a) changes in, or cash requirements for, our working capital needs; (b) interest expense, or the cash requirements necessary to service interest or principal payments on our debt, which reduces cash available to us; (c) tax payments that may represent a reduction in cash available to us; or (d) expense from our common stock warrant issued to the Tides Foundation, which is recurring and will be reflected in our financial results for the foreseeable future. The non-GAAP measures we use may be different from non-GAAP financial measures used by other companies, limiting their usefulness for comparison purposes. We compensate for these limitations by providing specific information regarding the GAAP items excluded from these non-GAAP financial measures. A reconciliation of these non-GAAP measures has been provided in the financial statement tables included in this press release and investors are encouraged to review the reconciliation.

About Upwork

Upwork is the world’s largest work marketplace that connects businesses with independent talent, as measured by GSV. We serve everyone from one-person startups to 30% of the Fortune 100 with a powerful, trust-driven platform that enables companies and freelancers to work together in new ways that unlock their potential. Our talent community earned over $2.3 billion on Upwork in 2020 across more than 10,000 skills, including website & app development, creative & design, customer support, finance & accounting, consulting, and operations. Learn more at www.upwork.com and join us on LinkedIn, Twitter, and Facebook.

Upwork is a registered trademark of Upwork Inc. All other product and brand names may be trademarks or registered trademarks of their respective owners.

UPWORK INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except for per share data)

(Unaudited)

  Three Months Ended 

December 31,
  Twelve Months Ended 

December 31,
  2020   2019   2020   2019
Revenue              
Marketplace $ 96,866       $ 72,189       $ 338,152       $ 268,284    
Managed services 9,287       8,099       35,476       32,278    
Total revenue 106,153       80,288       373,628       300,562    
Cost of revenue 28,778       22,937       104,267       88,144    
Gross profit 77,375       57,351       269,361       212,418    
Operating expenses              
Research and development 22,743       16,322       83,471       64,027    
Sales and marketing 34,530       25,572       133,225       95,891    
General and administrative 18,545       21,134       71,518       67,327    
Provision for transaction losses 901       1,199       3,555       3,905    
Total operating expenses 76,719       64,227       291,769       231,150    
Income (loss) from operations 656       (6,876 )     (22,408 )     (18,732 )  
Interest expense 138       259       778       1,306    
Other income, net (500 )     (1,634 )     (469 )     (3,407 )  
Income (loss) before income taxes 1,018       (5,501 )     (22,717 )     (16,631 )  
Income tax provision (93 )           (150 )     (28 )  
Net income (loss) $ 925       $ (5,501 )     $ (22,867 )     $ (16,659 )  
               
Net income (loss) per share, basic and diluted $ 0.01       $ (0.05 )     $ (0.19 )     $ (0.15 )  
Weighted-average shares used to compute net income (loss) per share, basic and diluted 123,398       112,690       118,699       109,815    

UPWORK INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands)

(Unaudited)

  As of December 31,
  2020   2019
ASSETS      
Current assets:      
Cash and cash equivalents $ 94,081       $ 48,392    
Marketable securities 75,570       85,481    
Funds held in escrow, including funds in transit 135,042       108,721    
Trade and client receivables, net 47,018       30,156    
Prepaid expenses and other current assets 9,090       7,885    
Total current assets 360,801       280,635    
Property and equipment, net 28,139       21,454    
Goodwill 118,219       118,219    
Intangible assets, net 667       3,335    
Operating lease asset 19,729       21,908    
Other assets, noncurrent 1,672       829    
Total assets $ 529,227       $ 446,380    
       
LIABILITIES AND STOCKHOLDERS’ EQUITY      
Current liabilities:      
Accounts payable $ 6,455       $ 652    
Escrow funds payable 135,042       108,721    
Debt, current 7,581       7,584    
Accrued expenses and other current liabilities 32,868       18,342    
Deferred revenue 16,801       13,799    
Total current liabilities 198,747       149,098    
Debt, noncurrent 3,142       10,699    
Operating lease liability, noncurrent 20,506       21,186    
Other liabilities, noncurrent 7,522       5,973    
Total liabilities 229,917       186,956    
       
Stockholders’ equity:      
Common stock 12       11    
Additional paid-in capital 494,122       431,370    
Accumulated deficit (194,824 )     (171,957 )  
Total stockholders’ equity 299,310       259,424    
Total liabilities and stockholders’ equity $ 529,227       $ 446,380    

UPWORK INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

  Three Months Ended 

December 31,
  Twelve Months Ended 

December 31,
  2020   2019   2020   2019
CASH FLOWS FROM OPERATING ACTIVITIES:              
Net income (loss) $ 925       $ (5,501 )     $ (22,867 )     $ (16,659 )  
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:              
Provision for transaction losses 265       1,040       2,919       3,118    
Depreciation and amortization 2,728       2,163       10,172       6,661    
Amortization of debt issuance costs 18       13       61       52    
Amortization of discount on purchases of marketable securities (9 )     (210 )     (320 )     (1,158 )  
Amortization of operating lease asset 933       886       3,860       3,945    
Tides Foundation common stock warrant expense 186       272       750       711    
Stock-based compensation expense 5,981       7,940       25,508       18,798    
Loss on disposal of fixed assets 44       14       44       14    
Changes in operating assets and liabilities:              
Trade and client receivables (7,510 )     (3,815 )     (20,000 )     (10,918 )  
Prepaid expenses and other assets (914 )     (662 )     (1,198 )     (2,069 )  
Operating lease liability (431 )     (473 )     (1,851 )     (1,453 )  
Accounts payable 735       (2,154 )     5,822       (1,457 )  
Accrued expenses and other liabilities 4,990       (4,016 )     15,438       (2,957 )  
Deferred revenue 1,012       3,560       4,027       4,430    
Net cash provided by (used in) operating activities 8,953       (943 )     22,365       1,058    
CASH FLOWS FROM INVESTING ACTIVITIES:              
Purchases of marketable securities (37,066 )     (36,836 )     (107,281 )     (168,786 )  
Proceeds from maturities of marketable securities 28,500       12,000       117,500       84,500    
Purchases of property and equipment (110 )     (522 )     (6,320 )     (10,752 )  
Internal-use software and platform development costs (2,478 )     (1,832 )     (8,045 )     (5,886 )  
Net cash used in investing activities (11,154 )     (27,190 )     (4,146 )     (100,924 )  
CASH FLOWS FROM FINANCING ACTIVITIES:              
Changes in escrow funds payable 6,912       (5,872 )     26,321       10,535    
Proceeds from exercises of stock options and common stock warrant 7,685       4,181       31,028       18,155    
Proceeds from borrowings on debt             18,000       50,000    
Repayment of debt (1,892 )     (1,893 )     (25,621 )     (55,679 )  
Proceeds from employee stock purchase plan 2,252       2,814       4,913       6,391    
Net cash provided by (used in) financing activities 14,957       (770 )     54,641       29,402    
NET CHANGE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH 12,756       (28,903 )     72,860       (70,464 )  
Cash, cash equivalents, and restricted cash—beginning of period 219,707       188,506       159,603       230,067    
Cash, cash equivalents, and restricted cash—end of period $ 232,463       $ 159,603       $ 232,463       $ 159,603    

The below table reconciles cash, cash equivalents, and restricted cash as reported in the condensed consolidated balance sheets to the total of the same amounts shown in the condensed consolidated statements of cash flows as of December 31, 2020 and 2019 (in thousands):

  As of December 31,
  2020   2019
Cash and cash equivalents $ 94,081      $ 48,392   
Restricted cash 3,340      2,490   
Funds held in escrow, including funds in transit 135,042      108,721   
Total cash, cash equivalents, and restricted cash as shown in the consolidated statement of cash flows $ 232,463      $ 159,603   

UPWORK INC.

COST OF REVENUE AND GROSS MARGIN

(In thousands)

(Unaudited)

  Three Months Ended December 31,   Twelve Months Ended December 31,
  2020   2019   Change   2020   2019   Change
Cost of revenue $ 28,778     $ 22,937     $ 5,841   25 %   $ 104,267     $ 88,144     $ 16,123   18 %
Components of cost of revenue:                          
Costs of freelancer services to deliver managed services 7,377     6,620     757   11 %   28,703     26,763     1,940   7 %
Other components of cost of revenue 21,401     16,317     5,084   31 %   75,564     61,381     14,183   23 %
Total gross margin 73 %   71 %         72 %   71 %      

UPWORK INC.

RECONCILIATION OF GAAP TO NON-GAAP RESULTS

(In thousands, except for per share data)

(Unaudited)

  Three Months Ended 

December 31,
  Twelve Months Ended 

December 31,
  2020   2019   2020   2019
GAAP Net Income (Loss) $ 925       $ (5,501 )     $ (22,867 )     $ (16,659 )  
Add back (deduct):              
Stock-based compensation 5,981       7,940       25,508       18,798    
Depreciation and amortization 2,728       2,163       10,172       6,661    
Interest expense 138       259       778       1,306    
Other income, net (500 )     (1,634 )     (469 )     (3,407 )  
Provision for income tax 93             150       28    
Tides Foundation common stock warrant expense 186       272       750       711    
Non-GAAP Adjusted EBITDA $ 9,551       $ 3,499       $ 14,022       $ 7,438    
               
Cost of Revenue Reconciliation:              
Cost of revenue, GAAP $ 28,778       $ 22,937       $ 104,267       $ 88,144    
Stock-based compensation (200 )     (130 )     (779 )     (456 )  
Cost of revenue, Non-GAAP $ 28,578       $ 22,807       $ 103,488       $ 87,688    
% of revenue, GAAP 27   %   29   %   28   %   29   %
% of revenue, Non-GAAP 27   %   28   %   28   %   29   %
               
Gross Profit Reconciliation:              
Gross profit, GAAP $ 77,375       $ 57,351       $ 269,361       $ 212,418    
Stock-based compensation 200       130       779       456    
Gross profit, Non-GAAP $ 77,575       $ 57,481       $ 270,140       $ 212,874    
% of revenue, GAAP 73   %   71   %   72   %   71   %
% of revenue, Non-GAAP 73   %   72   %   72   %   71   %
               
Operating Expenses Reconciliation:              
Research and development, GAAP $ 22,743       $ 16,322       $ 83,471       $ 64,027    
Stock-based compensation (2,497 )     (1,902 )     (9,783 )     (6,471 )  
Research and development, Non-GAAP $ 20,246       $ 14,420       $ 73,688       $ 57,556    
% of revenue, GAAP 21   %   20   %   22   %   21   %
% of revenue, Non-GAAP 19   %   18   %   20   %   19   %
               
Sales and marketing, GAAP $ 34,530       $ 25,572       $ 133,225       $ 95,891    
Stock-based compensation (988 )     (749 )     (4,440 )     (2,609 )  
Sales and marketing, Non-GAAP $ 33,542       $ 24,823       $ 128,785       $ 93,282    
% of revenue, GAAP 33   %   32   %   36   %   32   %
% of revenue, Non-GAAP 32   %   31   %   34   %   31   %
               
General and administrative, GAAP $ 18,545       $ 21,134       $ 71,518       $ 67,327    
Stock-based compensation (2,296 )     (5,159 )     (10,506 )     (9,262 )  
Amortization of intangible assets (667 )     (667 )     (2,668 )     (2,668 )  
Tides Foundation common stock warrant expense (186 )     (272 )     (750 )     (711 )  
General and administrative, Non-GAAP $ 15,396       $ 15,036       $ 57,594       $ 54,686    
% of revenue, GAAP 17   %   26   %   19   %   22   %
% of revenue, Non-GAAP 15   %   19   %   15   %   18   %
               
Income (Loss) from Operations Reconciliation:              
Income (loss) from operations, GAAP $ 656       $ (6,876 )     $ (22,408 )     $ (18,732 )  
Stock-based compensation 5,981       7,940       25,508       18,798    
Amortization of intangible assets 667       667       2,668       2,668    
Tides Foundation common stock warrant expense 186       272       750       711    
Income from operations, Non-GAAP $ 7,490       $ 2,003       $ 6,518       $ 3,445    
% of revenue, GAAP 1   %   -9   %   -6   %   -6   %
% of revenue, Non-GAAP 7   %   2   %   2   %   1   %
               
Net Income (Loss) Reconciliation:              
Net income (loss), GAAP $ 925       $ (5,501 )     $ (22,867 )     $ (16,659 )  
Stock-based compensation 5,981       7,940       25,508       18,798    
Amortization of intangible assets 667       667       2,668       2,668    
Tides Foundation common stock warrant expense 186       272       750       711    
Net income, Non-GAAP $ 7,759       $ 3,378       $ 6,059       $ 5,518    
% of revenue, GAAP 1   %   -7   %   -6   %   -6   %
% of revenue, Non-GAAP 7   %   4   %   2   %   2   %
               
Net Income (Loss) per Share Reconciliation:              
Weighted-average shares outstanding 123,398       112,690       118,699       109,815    
Net income (loss) per share, GAAP $ 0.01       $ (0.05 )     $ (0.19 )     $ (0.15 )  
Net income per share, Non-GAAP $ 0.06       $ 0.03       $ 0.05       $ 0.05    

Contact:

Investor Relations
[email protected]



Waitr Partners With Nextbite on Its Delivery-Only Restaurant Concept

Waitr Partners With Nextbite on Its Delivery-Only Restaurant Concept

LAFAYETTE, La.–(BUSINESS WIRE)–
Waitr Holdings Inc. (Nasdaq:WTRH) (“Waitr” or the “Company”), a leader in on-demand food ordering and delivery, today announced the first group of delivery-only restaurant concepts have been added to the Waitr and Bite Squad platforms via a new partnership with Nextbite for food delivery from virtual brands – also known as ghost kitchens. With this new collaboration, customers of Waitr and Bite Squad can enjoy a significant increase in restaurant choices.

Delivery-only “virtual” restaurant locations are popping up all over the nation, following mass shutdowns and limitations on dine-in capacity and increased demand for off-premise meals. Nextbite, a pioneer in the virtual restaurant space and food on-demand revolution, has created the concept with high-quality, chef-inspired menus available through the Waitr and Bite Squad apps.

Virtual restaurant brands available via the Waitr and Bite Squad apps include Monster Mac, Wild Wild Wings, CraveBurger, Grilled Cheese Society, Firebelly Wings, Hotbox by Wiz, Miss Mazy’s, The Big Melt, The Wing Dynasty, and Tossitup.

According to Nextbite, each concept is backed by data and carefully crafted to dish out the very items customers crave. The Nextbite team used analytics from a variety of factors to develop first-in-class, proven brands.

“This new partnership with Nextbite boosts Waitr’s promise to provide a robust restaurant selection to our customers,” said Carl Grimstad, CEO and Chairman of Waitr. “The addition of these new and diverse food offerings through the virtual kitchen strengthens our position in many markets.”

“Waitr is a huge player within the restaurant space and we are thrilled to partner with them to help drive more orders and revenue for both our virtual kitchen and brick and mortar partners,” stated Alex Canter, the Founder and CEO of Ordermark, owner of Nextbite.

Nextbite, a virtual kitchen company, creates delivery-only restaurant concepts with high-quality, chef-inspired menus available through delivery apps. Together, these two companies help restaurants increase efficiency and grow profits, creating successful food service across the country.

About Waitr Holdings Inc.

Founded in 2013 and based in Lafayette, Louisiana, Waitr is a leader in on-demand food ordering and delivery. Waitr, and its sister brand Bite Squad, connects local restaurants and grocery stores to hungry diners in underserved U.S. markets. Together they are a convenient way to discover, order and receive great food from local restaurants, grocery stores and national chains. As of September 30, 2020, Waitr and Bite Squad operated in small and medium sized markets in the United States in over 700 cities.

Investors

[email protected]

KEYWORDS: United States North America Louisiana

INDUSTRY KEYWORDS: Restaurant/Bar Food/Beverage Retail Mobile/Wireless Technology

MEDIA:

Flowserve Corporation Reports Fourth Quarter and Full Year 2020 Results; Issues 2021 Financial Guidance

Flowserve Corporation Reports Fourth Quarter and Full Year 2020 Results; Issues 2021 Financial Guidance

  • Delivered Reported Fourth Quarter EPS of $0.43 and Adjusted EPS of $0.53
  • Generated strong fourth quarter and full-year free cash flow of $185 million and $253 million, respectively
  • Flowserve 2.0 transformation efforts limited fourth quarter decremental adjusted margins to 14%
  • Commercialized RedRaven, a global IoT offering, to help reduce customer operating costs

DALLAS–(BUSINESS WIRE)–
Flowserve Corporation (NYSE: FLS), a leading provider of flow control products and services for the global infrastructure markets, today announced its financial results for the fourth quarter and full year ended December 31, 2020.

Fourth Quarter 2020 Highlights (all comparisons to the 2019 fourth quarter, unless otherwise noted)1

  • Reported Earnings Per Share (EPS) of $0.43 and Adjusted EPS2 of $0.53

    • Reported EPS includes after-tax adjusted items of approximately $12.9 million, including realignment, transformation and below-the-line foreign exchange impacts
  • Total bookings were $825.1 million, down 21.6%, or 22.7% on a constant currency basis and up modestly sequentially

    • Original equipment bookings were $404.7 million, or 49% of total bookings, down 24.4%, or 25.8% on a constant currency basis
    • Aftermarket bookings were $420.4 million, or 51% of total bookings, down 18.7%, or 19.5% on a constant currency basis
  • Sales were $985.3 million, down 7.8%, or 8.9% on a constant currency basis

    • Original equipment sales were $506.9 million, down 7.1%, or 9.4% on a constant currency basis
    • Aftermarket sales were $478.4 million, down 8.4%, or 9.3% on a constant currency basis
  • Reported gross and operating margins were 30.0% and 9.7%, respectively

    • Adjusted gross and operating margins3 were 30.7% and 11.3%, respectively
  • Backlog at December 31, 2020 was $1.9 billion, down 14.0% versus prior year

Full Year 2020 Highlights (all comparisons to full year 2019, unless otherwise noted)

  • Reported EPS of $0.89 and Adjusted EPS2 of $1.74

    • Reported EPS includes after-tax adjusted items of approximately $111.1 million, including realignment, transformation, below-the-line foreign exchange impacts and certain non-cash impairments
  • Total bookings were $3.41 billion, down 19.5%, or 18.9% on a constant currency basis

    • Original equipment bookings were $1.62 billion, or 48% of total bookings, down 26.7%, or 26.4% on a constant currency basis
    • Aftermarket bookings were $1.79 billion, or 52% of total bookings, down 11.7%, or 10.9% on a constant currency basis
  • Sales were $3.73 billion, down 5.4%, or 4.9% on a constant currency basis

    • Original equipment sales were $1.90 billion, down 3.1%, or 2.9% on a constant currency basis
    • Aftermarket sales were $1.83 billion, down 7.6%, or 6.9% on a constant currency basis
  • Reported gross and operating margins of 30.0% and 6.7%, respectively

    • Adjusted gross and operating margins3 were 31.2% and 9.8%, respectively

“In a challenging market environment, we delivered solid performance in the fourth quarter including meaningful working capital improvements and free cash flow of $185 million. Additionally, our associates continued to operate safely and efficiently throughout the pandemic to meet the needs of our customers, while also delivering meaningful progress on our transformation program,” said Scott Rowe, Flowserve’s president and chief executive officer. “In light of the ongoing COVID-induced market headwinds over the past year, we accelerated our Flowserve 2.0 transformation cost reduction initiatives and took over $100 million of costs out of the business during 2020. This swift and decisive action and our ongoing operational performance enabled us to limit decremental adjusted operating margins to only 14 percent in the fourth quarter.”

“In 2021 we are returning our focus to the growth and optimization aspects of the Flowserve 2.0 agenda,” added Rowe. “Innovation and new product development are key aspects of our growth strategy, and we expect to build upon the momentum we achieved in 2020, which included 21 commercial launches of new, redesigned or upgraded products. Additionally, this year we further differentiated our product offering by commercializing RedRaven, Flowserve’s IoT offering to optimize our customers’ flow control processes and lower their operating costs.”

2021 Guidance4

Flowserve is providing Reported and Adjusted EPS guidance for 2021, as well as certain other financial metrics, as shown in the table below.

2021 Target Range

Revenues

Down 4.0% to 7.0%

Reported Earnings Per Share

$1.15 – $1.40

Adjusted Earnings Per Share

$1.30 – $1.55

Net interest expense

$55 – $60 million

Adjusted Tax rate

22% to 24%

Flowserve’s 2021 Adjusted EPS target range excludes expected realignment charges of approximately $25 million, as well as the potential impact of below-the-line foreign currency effects and certain other discrete items. In a change of our approach in 2021, Flowserve 2.0 transformation-related expenses of approximately 5 cents per share will now be included in both our reported and adjusted EPS. Additionally, both the Reported and the Adjusted EPS target range includes the expected revenue decrease of approximately 4.0 to 7.0 percent year-over-year, and is based on current foreign currency rates and commodity prices, 2020 year-end backlog, expected bookings levels and market conditions, the reset of annual incentive performance goals, a broad-based merit increase, modest above-the-line foreign currency benefit, net interest expense in the range of $55 to $60 million and an adjusted tax rate of 22 to 24 percent. The quarterly phasing of expected 2021 earnings is anticipated in-line with Flowserve’s traditional seasonality.

Comment on Outlook

Rowe concluded, “The impact of the COVID-driven downturn impacted our financial performance in 2020, but due to our late-cycle nature, it will have a larger impact to our business in 2021 given our lower starting backlog and the ongoing management of the pandemic across our global footprint. However, I am increasingly optimistic, as the pandemic gets further contained, that our end markets will be well-positioned for significant growth.”

“We are encouraged by the progress of the vaccines, increased global mobility, stability in commodity prices, and the pent-up demand for our parts and services to existing infrastructure. Since we cannot accurately predict the timing of the inflection, our guidance only reflects modest end-market improvement. We do believe, assuming progress continues against the pandemic, that we will return to bookings growth this calendar year which would position us for improved financial performance in 2022.”

Fourth Quarter 2020 Results Conference Call

Flowserve will host its conference call with the financial community on Wednesday, February 24th at 11:00 AM Eastern. Scott Rowe, president and chief executive officer, as well as other members of the management team will be presenting. The call can be accessed by shareholders and other interested parties at www.flowserve.com under the “Investor Relations” section.

1

Prior period comparisons are impacted by the accounting revision related to incurred but not reported accruals for expected future asbestos litigation as well as certain other non-material adjustments further detailed in “Revisions to Prior Periods” section.

2

See Reconciliation of Non-GAAP Measures table for detailed reconciliation of reported results to adjusted measures.

3

Adjusted gross and operating margins are calculated by dividing adjusted gross profit and adjusted operating income, respectively, by revenues. Adjusted gross profit and adjusted operating income are derived by excluding the adjusted items. See reconciliation of Non-GAAP Measures table for detailed reconciliation.

4

Adjusted 2021 EPS will exclude the Company’s realignment expenses, the impact from other specific one-time events and below-the-line foreign currency effects and utilizes year-end 2020 FX rates and approximately 131 million fully diluted shares.

FX headwind is calculated by comparing the difference between the actual average FX rates of 2020 and the year-end 2020 spot rates both as applied to our 2021 expectations, divided by the number of shares expected for 2021.

About Flowserve

Flowserve Corp. is one of the world’s leading providers of fluid motion and control products and services. Operating in more than 50 countries, the company produces engineered and industrial pumps, seals and valves as well as a range of related flow management services. More information about Flowserve can be obtained by visiting the company’s Web site at www.flowserve.com.

Safe Harbor Statement: This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Words or phrases such as, “may,” “should,” “expects,” “could,” “intends,” “plans,” “anticipates,” “estimates,” “believes,” “forecasts,” “predicts” or other similar expressions are intended to identify forward-looking statements, which include, without limitation, earnings forecasts, statements relating to our business strategy and statements of expectations, beliefs, future plans and strategies and anticipated developments concerning our industry, business, operations and financial performance and condition.

The forward-looking statements included in this news release are based on our current expectations, projections, estimates and assumptions. These statements are only predictions, not guarantees. Such forward-looking statements are subject to numerous risks and uncertainties that are difficult to predict. These risks and uncertainties may cause actual results to differ materially from what is forecast in such forward-looking statements, and include, without limitation, the following: the impact of the global outbreak of COVID-19 on our business and operations; a portion of our bookings may not lead to completed sales, and our ability to convert bookings into revenues at acceptable profit margins; changes in global economic conditions and the potential for unexpected cancellations or delays of customer orders in our reported backlog; our dependence on our customers’ ability to make required capital investment and maintenance expenditures; if we are not able to successfully execute and realize the expected financial benefits from our strategic transformation and realignment initiatives, our business could be adversely affected; risks associated with cost overruns on fixed-fee projects and in taking customer orders for large complex custom engineered products; the substantial dependence of our sales on the success of the oil and gas, chemical, power generation and water management industries; the adverse impact of volatile raw materials prices on our products and operating margins; economic, political and other risks associated with our international operations, including military actions, trade embargoes, epidemics or pandemics or changes to tariffs or trade agreements that could affect customer markets, particularly North African, Russian and Middle Eastern markets and global oil and gas producers, and non-compliance with U.S. export/re-export control, foreign corrupt practice laws, economic sanctions and import laws and regulations; increased aging and slower collection of receivables, particularly in Latin America and other emerging markets; our exposure to fluctuations in foreign currency exchange rates, including in hyperinflationary countries such as Venezuela and Argentina; our furnishing of products and services to nuclear power plant facilities and other critical processes; potential adverse consequences resulting from litigation to which we are a party, such as litigation involving asbestos-containing material claims; expectations regarding acquisitions and the integration of acquired businesses; our relative geographical profitability and its impact on our utilization of deferred tax assets, including foreign tax credits; the potential adverse impact of an impairment in the carrying value of goodwill or other intangible assets; our dependence upon fourth-party suppliers whose failure to perform timely could adversely affect our business operations; the highly competitive nature of the markets in which we operate; environmental compliance costs and liabilities; potential work stoppages and other labor matters; access to public and private sources of debt financing; our inability to protect our intellectual property in the U.S., as well as in foreign countries; obligations under our defined benefit pension plans; our internal control over financial reporting may not prevent or detect misstatements because of its inherent limitations, including the possibility of human error, the circumvention or overriding of controls, or fraud; the recording of increased deferred tax asset valuation allowances in the future or the impact of tax law changes on such deferred tax assets could affect our operating results; our information technology infrastructure could be subject to service interruptions, data corruption, cyber-based attacks or network security breaches, which could disrupt our business operations and result in the loss of critical and confidential information; ineffective internal controls could impact the accuracy and timely reporting of our business and financial results; and other factors described from time to time in our filings with the Securities and Exchange Commission.

All forward-looking statements included in this news release are based on information available to us on the date hereof, and we assume no obligation to update any forward-looking statement.

The Company reports its financial results in accordance with U.S. generally accepted accounting principles (GAAP). However, management believes that non-GAAP financial measures which exclude certain non-recurring items present additional useful comparisons between current results and results in prior operating periods, providing investors with a clearer view of the underlying trends of the business. Management also uses these non-GAAP financial measures in making financial, operating, planning and compensation decisions and in evaluating the Company’s performance. Throughout our materials we refer to non-GAAP measures as “Adjusted.” Non-GAAP financial measures, which may be inconsistent with similarly captioned measures presented by other companies, should be viewed in addition to, and not as a substitute for, the Company’s reported results prepared in accordance with GAAP.

CONSOLIDATED STATEMENTS OF INCOME
(Unaudited)

Three Months Ended December 31,

(Amounts in thousands, except per share data)

2020

 

2019

 
Sales

$

985,308

 

$

1,068,179

 

Cost of sales

 

(689,913

)

 

(718,598

)

Gross profit

 

295,395

 

 

349,581

 

Selling, general and administrative expense

 

(202,722

)

 

(247,576

)

Net earnings from affiliates

 

2,627

 

 

2,425

 

Operating income

 

95,300

 

 

104,430

 

Interest expense

 

(16,779

)

 

(12,954

)

Interest income

 

604

 

 

1,915

 

Other income (expense), net

 

(17,811

)

 

(2,467

)

Earnings before income taxes

 

61,314

 

 

90,924

 

Provision for income taxes

 

(856

)

 

(16,886

)

Net earnings, including noncontrolling interests

 

60,458

 

 

74,038

 

Less: Net earnings attributable to noncontrolling interests

 

(3,565

)

 

(1,453

)

Net earnings attributable to Flowserve Corporation

$

56,893

 

$

72,585

 

 
Net earnings per share attributable to Flowserve Corporation common shareholders:
Basic

$

0.44

 

$

0.55

 

Diluted

 

0.43

 

 

0.55

 

RECONCILIATION OF NON-GAAP MEASURES
(Unaudited)
 

Three Months Ended December 31, 2020

(Amounts in thousands, except per share data)

As Reported (a)

 

Realignment (1)

 

 

Other Items

 

 

As Adjusted

 
Sales

$

985,308

 

$

 

$

 

$

985,308

 

Gross profit

 

295,395

 

 

(6,662

)

 

 

 

302,057

 

Gross margin

 

30.0

%

 

 

 

 

 

30.7

%

 
Selling, general and administrative expense

 

(202,722

)

 

(3,092

)

 

(6,712

)

(3)

 

(192,918

)

 
Operating income

 

95,300

 

 

(9,754

)

 

(6,712

)

 

111,766

 

Operating income as a percentage of sales

 

9.7

%

 

 

 

 

 

11.3

%

 
Interest and other expense, net

 

(33,986

)

 

 

 

(15,106

)

(4)

 

(18,880

)

 
Earnings before income taxes

 

61,314

 

 

(9,754

)

 

(21,818

)

 

92,886

 

Provision for income taxes

 

(856

)

 

2,414

 

(2)

 

16,236

 

(5)

 

(19,506

)

Tax Rate

 

1.4

%

 

24.7

%

 

74.4

%

 

21.0

%

 
Net earnings attributable to Flowserve Corporation

$

56,893

 

$

(7,340

)

$

(5,582

)

$

69,815

 

 
Net earnings per share attributable to Flowserve Corporation common shareholders:
Basic

$

0.44

 

$

(0.06

)

$

(0.04

)

$

0.54

 

Diluted

 

0.43

 

 

(0.06

)

 

(0.04

)

 

0.53

 

 
Basic number of shares used for calculation

 

130,343

 

 

130,343

 

 

130,343

 

 

130,343

 

Diluted number of shares used for calculation

 

130,995

 

 

130,995

 

 

130,995

 

 

130,995

 

 
(a) Reported in conformity with U.S. GAAP
 
Notes:
(1) Represents realignment expense incurred as a result of realignment programs
(2) Includes tax impact of items above
(3) Represents Flowserve 2.0 transformation efforts
(4) Represents below-the-line foreign exchange impacts
(5) Includes tax impact of items above and $13.2 million benefit related to legal entity simplification and restructuring
RECONCILIATION OF NON-GAAP MEASURES
(Unaudited)
 

Three Months Ended December 31, 2019

(Amounts in thousands, except per share data)

As Reported (a)

 

Realignment (1)

 

 

Other Items

 

 

As Adjusted

 
Sales

$

1,068,179

 

$

 

$

 

$

1,068,179

 

Gross profit

 

349,581

 

 

(4,451

)

 

(196

)

(3)

 

354,228

 

Gross margin

 

32.7

%

 

 

 

 

 

33.2

%

 
Selling, general and administrative expense

 

(247,576

)

 

(4,315

)

 

(10,287

)

(4)

 

(232,974

)

 
Operating income

 

104,430

 

 

(8,766

)

 

(10,483

)

 

123,679

 

Operating income as a percentage of sales

 

9.8

%

 

 

 

 

 

11.6

%

 
Interest and other expense, net

 

(13,506

)

 

 

 

(671

)

(5)

 

(12,835

)

 
Earnings before income taxes

 

90,924

 

 

(8,766

)

 

(11,154

)

 

110,844

 

Provision for income taxes

 

(16,886

)

 

5,679

 

(2)

 

2,001

 

(6)

 

(24,566

)

Tax Rate

 

18.6

%

 

64.8

%

 

17.9

%

 

22.2

%

 
Net earnings attributable to Flowserve Corporation

$

72,585

 

$

(3,087

)

$

(9,153

)

$

84,825

 

 
Net earnings per share attributable to Flowserve Corporation common shareholders:
Basic

$

0.55

 

$

(0.02

)

$

(0.07

)

$

0.65

 

Diluted

 

0.55

 

 

(0.02

)

 

(0.07

)

 

0.64

 

 
Basic number of shares used for calculation

 

130,863

 

 

130,863

 

 

130,863

 

 

130,863

 

Diluted number of shares used for calculation

 

131,783

 

 

131,783

 

 

131,783

 

 

131,783

 

 
(a) Reported in conformity with U.S. GAAP
 
Notes:
(1) Represents realignment expense incurred as a result of realignment programs
(2) Includes tax impact of items above and uncertain tax position release of $4.0 million
(3) Represents Voluntary Retirement Program expense
(4) Represents $7.0 million related to Flowserve 2.0 transformation efforts and $3.3 million related to voluntary retirement program expense
(5) Represents below-the-line foreign exchange impacts
(6) Includes tax impact of items above
SEGMENT INFORMATION
(Unaudited)
 
FLOWSERVE PUMP DIVISION

Three Months Ended December 31

(Amounts in millions, except percentages)

2020

 

2019

Bookings

$

566.5

 

$

756.0

 

Sales

 

695.7

 

 

739.5

 

Gross profit

 

207.7

 

 

245.6

 

Gross profit margin

 

29.9

%

 

33.2

%

SG&A

 

126.1

 

 

146.6

 

Segment operating income

 

84.2

 

 

101.4

 

Segment operating income as a percentage of sales

 

12.1

%

 

13.7

%

 
FLOW CONTROL DIVISION

Three Months Ended December 31,

(Amounts in millions, except percentages)

2020

 

2019

Bookings

$

258.4

 

$

298.6

 

Sales

 

290.7

 

 

330.2

 

Gross profit

 

92.8

 

 

111.8

 

Gross profit margin

 

31.9

%

 

33.9

%

SG&A

 

41.4

 

 

54.4

 

Segment operating income

 

51.4

 

 

57.3

 

Segment operating income as a percentage of sales

 

17.7

%

 

17.4

%

CONSOLIDATED STATEMENTS OF INCOME
 

Year Ended December 31,

(Amounts in thousands, except per share data)

2020

 

2019

 

2018

 
Sales

$

3,728,134

 

$

3,939,697

 

$

3,835,699

 

Cost of sales

 

(2,611,365

)

 

(2,650,354

)

 

(2,644,830

)

Gross profit

 

1,116,769

 

 

1,289,343

 

 

1,190,869

 

Selling, general and administrative expense

 

(878,245

)

 

(913,203

)

 

(966,584

)

Loss on sale of business

 

 

 

 

 

(7,727

)

Net earnings from affiliates

 

11,753

 

 

10,483

 

 

11,143

 

Operating income

 

250,277

 

 

386,623

 

 

227,701

 

Interest expense

 

(57,386

)

 

(54,980

)

 

(58,160

)

Interest income

 

4,175

 

 

8,409

 

 

6,465

 

Other income (expense), net

 

(10,254

)

 

(17,619

)

 

(19,569

)

Earnings before income taxes

 

186,812

 

 

322,433

 

 

156,437

 

Provision for income taxes

 

(60,031

)

 

(75,493

)

 

(46,550

)

Net earnings, including noncontrolling interests

 

126,781

 

 

246,940

 

 

109,887

 

Less: Net earnings attributable to noncontrolling interests

 

(10,455

)

 

(8,112

)

 

(5,379

)

Net earnings attributable to Flowserve Corporation

$

116,326

 

$

238,828

 

$

104,508

 

 
Net earnings per share attributable to Flowserve Corporation common shareholders:
Basic

$

0.89

 

$

1.82

 

$

0.80

 

Diluted

 

0.89

 

 

1.81

 

 

0.80

 

RECONCILIATION OF NON-GAAP MEASURES
(Unaudited)
 

Year Ended December 31, 2020

(Amounts in thousands, except per share data)

As Reported (a)

 

Realignment (1)

 

 

Other Items

 

 

As Adjusted

 
Sales

$

3,728,134

 

$

 

$

 

$

3,728,134

 

Gross profit

 

1,116,769

 

 

(47,297

)

 

 

 

1,164,066

 

Gross margin

 

30.0

%

 

 

 

 

 

31.2

%

 
Selling, general and administrative expense

 

(878,245

)

 

(34,773

)

 

(34,269

)

(3)

 

(809,203

)

 
Operating income

 

250,277

 

 

(82,070

)

 

(34,269

)

 

366,616

 

Operating income as a percentage of sales

 

6.7

%

 

 

 

 

 

9.8

%

 
Interest and other expense, net

 

(63,465

)

 

 

 

(5,854

)

(4)

 

(57,611

)

 
Earnings before income taxes

 

186,812

 

 

(82,070

)

 

(40,123

)

 

309,005

 

Provision for income taxes

 

(60,031

)

 

12,560

 

(2)

 

(1,428

)

(5)

 

(71,163

)

Tax Rate

 

32.1

%

 

15.3

%

 

-3.6

%

 

23.0

%

 
Net earnings attributable to Flowserve Corporation

$

116,326

 

$

(69,510

)

$

(41,551

)

$

227,387

 

 
Net earnings per share attributable to Flowserve Corporation common shareholders:
Basic

$

0.89

 

$

(0.53

)

$

(0.32

)

$

1.74

 

Diluted

 

0.89

 

 

(0.53

)

 

(0.32

)

 

1.74

 

 
Basic number of shares used for calculation

 

130,395

 

 

130,395

 

 

130,395

 

 

130,395

 

Diluted number of shares used for calculation

 

131,050

 

 

131,050

 

 

131,050

 

 

131,050

 

 
(a) Reported in conformity with U.S. GAAP
 
Notes:
(1) Represents realignment expense incurred as a result of realignment programs
(2) Includes tax impact of items above
(3) Includes $22.7 million related to Flowserve 2.0 transformation efforts and $11.5 million related to discrete asset write-downs
(4) Represents below-the-line foreign exchange impacts
(5) Includes tax impact of items above, $25.4 million related to Italian tax valuation allowance and $15.6 million benefit related to legal entity simplification and restructuring
RECONCILIATION OF NON-GAAP MEASURES
(Unaudited)
 

Year Ended December 31, 2019

(Amounts in thousands, except per share data)

As Reported (a)

 

Realignment (1)

 

 

Other Items

 

 

As Adjusted

 
Sales

$

3,939,697

 

$

 

$

 

$

3,939,697

 

Gross profit

 

1,289,343

 

 

(17,234

)

 

(196

)

(3)

 

1,306,772

 

Gross margin

 

32.7

%

 

 

 

 

 

33.2

%

 
Selling, general and administrative expense

 

(913,203

)

 

9,304

 

 

(31,331

)

(4)

 

(891,176

)

 
Operating income

 

386,623

 

 

(7,930

)

 

(31,527

)

 

426,079

 

Operating income as a percentage of sales

 

9.8

%

 

 

 

 

 

10.8

%

 
Interest and other expense, net

 

(64,190

)

 

 

 

(14,459

)

(5)

 

(49,731

)

 
Earnings before income taxes

 

322,433

 

 

(7,930

)

 

(45,986

)

 

376,348

 

Provision for income taxes

 

(75,493

)

 

7,618

 

(2)

 

10,604

 

(6)

 

(93,715

)

Tax Rate

 

23.4

%

 

96.1

%

 

23.1

%

 

24.9

%

 
Net earnings attributable to Flowserve Corporation

$

238,828

 

$

(312

)

$

(35,382

)

$

274,521

 

 
Net earnings per share attributable to Flowserve Corporation common shareholders:
Basic

$

1.82

 

$

 

$

(0.27

)

$

2.10

 

Diluted

 

1.81

 

 

 

 

(0.27

)

 

2.08

 

 
Basic number of shares used for calculation

 

131,034

 

 

131,034

 

 

131,034

 

 

131,034

 

Diluted number of shares used for calculation

 

131,719

 

 

131,719

 

 

131,719

 

 

131,719

 

 
(a) Reported in conformity with U.S. GAAP
 
Notes:
(1) Represents realignment (expense) income incurred as a result of realignment programs. Income in selling, general and administrative due to gains from the sales of non-strategic manufacturing facilities that are included in our Realignment Programs
(2) Includes tax impact of items above and uncertain tax position release of $4.0 million
(3) Represents Voluntary Retirement Program expense
(4) Represents $28.0 million related to Flowserve 2.0 transformation efforts and $3.3 million related to voluntary retirement program expense
(5) Represents below-the-line foreign exchange impacts
(6) Includes tax impact of items above
SEGMENT INFORMATION
(Unaudited)
 
FLOWSERVE PUMP DIVISION

Year Ended December 31,

(Amounts in millions, except percentages)

2020

 

2019

 

2018

Bookings

$

2,358.4

 

$

3,007.9

 

$

2,753.5

 

Sales

 

2,675.7

 

 

2,706.3

 

 

2,623.3

 

Gross profit

 

811.4

 

 

899.3

 

 

775.7

 

Gross profit margin

 

30.3

%

 

33.2

%

 

29.6

%

SG&A

 

552.2

 

 

566.3

 

 

578.9

 

Loss on sale of business

 

 

 

 

 

(7.7

)

Segment operating income

 

271.0

 

 

343.5

 

 

201.0

 

Segment operating income as a percentage of sales

 

10.1

%

 

12.7

%

 

7.7

%

 
 
FLOW CONTROL DIVISION

Year Ended December 31,

(Amounts in millions, except percentages)

2020

 

2019

 

2018

Bookings

$

1,065.8

 

$

1,240.9

 

$

1,274.3

 

Sales

 

1,057.5

 

 

1,238.9

 

 

1,218.8

 

Gross profit

 

321.9

 

 

405.5

 

 

419.9

 

Gross profit margin

 

30.4

%

 

32.7

%

 

34.5

%

SG&A

 

196.3

 

 

213.6

 

 

215.0

 

Segment operating income

 

125.6

 

 

191.9

 

 

204.2

 

Segment operating income as a percentage of sales

 

11.9

%

 

15.5

%

 

16.8

%

Fourth Quarter and Full Year 2020 – Segment Results
(dollars in millions, comparison vs. 2019 fourth quarter and full year, unaudited)
 

FPD

 

FCD

4th Qtr

 

YTD

 

4th Qtr

 

YTD

Bookings

$

566.5

 

$

2,358.4

 

$

258.4

 

$

1,065.8

 

– vs. prior year

 

-25.1

%

 

-21.6

%

 

-13.5

%

 

-14.1

%

– on constant currency

 

-26.0

%

 

-20.9

%

 

-15.1

%

 

-13.8

%

 
Sales

$

695.7

 

$

2,675.7

 

$

290.7

 

$

1,057.5

 

– vs. prior year

 

-5.9

%

 

-1.1

%

 

-12.0

%

 

-14.6

%

– on constant currency

 

-7.4

%

 

-0.4

%

 

-12.3

%

 

-14.7

%

 
Gross Profit

$

207.7

 

$

811.4

 

$

92.8

 

$

321.9

 

– vs. prior year

 

-15.4

%

 

-9.8

%

 

-17.0

%

 

-20.6

%

 
Gross Margin (% of sales)

 

29.9

%

 

30.3

%

 

31.9

%

 

30.4

%

– vs. prior year (in basis points) (330) bps (290) bps (200) bps (230) bps
 
Operating Income

$

84.2

 

$

271.0

 

$

51.4

 

$

125.6

 

– vs. prior year

 

-17.0

%

 

-21.1

%

 

-10.3

%

 

-34.5

%

– on constant currency

 

-16.3

%

 

-18.5

%

 

-2.7

%

 

-34.5

%

 
Operating Margin (% of sales)

 

12.1

%

 

10.1

%

 

17.7

%

 

11.9

%

– vs. prior year (in basis points) (160) bps (260) bps 30 bps (360) bps
 
Adjusted Operating Income *

$

91.1

 

$

329.6

 

$

52.1

 

$

141.9

 

– vs. prior year

 

-13.0

%

 

-3.6

%

 

-15.6

%

 

-28.4

%

– on constant currency

 

-12.3

%

 

-1.0

%

 

-8.6

%

 

-28.3

%

 
Adj. Oper. Margin (% of sales)*

 

13.1

%

 

12.3

%

 

17.9

%

 

13.4

%

– vs. prior year (in basis points) (110) bps (30) bps (80) bps (260) bps
 
Backlog

$

1,236.9

 

$

623.1

 

 
* Adjusted Operating Income and Adjusted Operating Margin exclude realignment charges and other specific discrete items
CONSOLIDATED BALANCE SHEETS
 

December 31,

 

December 31,

(Amounts in thousands, except par value)

2020

 

2019

 
ASSETS
Current assets:
Cash and cash equivalents

$

1,095,274

 

$

670,980

 

Accounts receivable, net

 

753,462

 

 

795,538

 

Contract assets, net

 

277,734

 

 

272,914

 

Inventories, net

 

667,228

 

 

660,837

 

Prepaid expenses and other

 

110,635

 

 

106,478

 

Total current assets

 

2,904,333

 

 

2,506,747

 

Property, plant and equipment, net

 

556,873

 

 

563,564

 

Operating lease right-of-use assets, net

 

208,125

 

 

186,218

 

Goodwill

 

1,224,886

 

 

1,193,010

 

Deferred taxes

 

30,538

 

 

54,879

 

Other intangible assets, net

 

168,496

 

 

180,805

 

Other assets, net

 

221,426

 

 

253,054

 

Total assets

$

5,314,677

 

$

4,938,277

 

 
LIABILITIES AND EQUITY
Current liabilities:
Accounts payable

$

440,199

 

$

447,582

 

Accrued liabilities

 

463,222

 

 

401,385

 

Contract liabilities

 

194,227

 

 

221,095

 

Debt due within one year

 

8,995

 

 

11,272

 

Operating lease liabilities

 

34,990

 

 

36,108

 

Total current liabilities

 

1,141,633

 

 

1,117,442

 

Long-term debt due after one year

 

1,717,911

 

 

1,365,977

 

Operating lease liabilities

 

176,246

 

 

151,523

 

Retirement obligations and other liabilities

 

516,087

 

 

530,994

 

Shareholders’ equity:
Common shares, $1.25 par value

 

220,991

 

 

220,991

 

Shares authorized – 305,000
Shares issued – 176,793 and 176,793, respectfully
Capital in excess of par value

 

502,227

 

 

501,045

 

Retained earnings

 

3,656,449

 

 

3,652,244

 

Treasury shares, at cost – 46,768 and 46,262 shares, respectively

 

(2,059,309

)

 

(2,051,583

)

Deferred compensation obligation

 

6,164

 

 

8,334

 

Accumulated other comprehensive loss

 

(594,052

)

 

(584,292

)

Total Flowserve Corporation shareholders’ equity

 

1,732,470

 

 

1,746,739

 

Noncontrolling interests

 

30,330

 

 

25,602

 

Total equity

 

1,762,800

 

 

1,772,341

 

Total liabilities and equity

$

5,314,677

 

$

4,938,277

 

CONSOLIDATED STATEMENTS OF CASH FLOWS
 

Year Ended December 31,

(Amounts in thousands)

2020

 

2019

 

2018

 
Cash flows – Operating activities:
Net earnings, including noncontrolling interests

$

126,781

 

$

246,940

 

$

109,887

 

Adjustments to reconcile net earnings to net cash provided (used) by operating activities:
Depreciation

 

86,175

 

 

92,042

 

 

95,820

 

Amortization of intangible and other assets

 

14,578

 

 

13,862

 

 

16,653

 

Loss on disposition of business

 

 

 

 

 

7,727

 

Stock-based compensation

 

27,252

 

 

23,882

 

 

19,912

 

Provision for U.S. Tax Cuts and Jobs Act of 2017

 

 

 

 

 

(5,654

)

Foreign currency, asset impairment and other non-cash adjustments

 

21,051

 

 

(11,724

)

 

36,052

 

Change in assets and liabilities:
Accounts receivable, net

 

45,648

 

 

2,883

 

 

(25,448

)

Inventories, net

 

15,306

 

 

(31,058

)

 

(29,314

)

Contract assets, net

 

4,258

 

 

(45,220

)

 

(24,411

)

Prepaid expenses and other assets, net

 

34,262

 

 

(9,455

)

 

(15,491

)

Contract liabilities

 

(34,066

)

 

19,699

 

 

32,955

 

Accounts payable

 

(22,571

)

 

24,678

 

 

7,589

 

Accrued liabilities and income taxes payable

 

50,203

 

 

12,418

 

 

(15,248

)

Retirement obligations and other

 

3,636

 

 

(3,357

)

 

(26,595

)

Net deferred taxes

 

(61,976

)

 

(11,493

)

 

6,397

 

Net cash flows provided (used) by operating activities

 

310,537

 

 

324,097

 

 

190,831

 

Cash flows – Investing activities:
Capital expenditures

 

(57,405

)

 

(75,716

)

 

(83,993

)

Proceeds from disposal of assets

 

15,705

 

 

42,333

 

 

6,190

 

Payments for disposition of business

 

 

 

 

 

(3,663

)

Net cash flows provided (used) by investing activities

 

(41,700

)

 

(33,383

)

 

(81,466

)

Cash flows – Financing activities:
Payments on long-term debt

 

(191,258

)

 

(105,000

)

 

(60,000

)

Proceeds from issuance of senior notes

 

498,280

 

 

 

 

 

Payment of deferred loan cost

 

(4,572

)

 

 

 

 

Proceeds from short-term financing

 

 

 

75,000

 

 

 

Payments on short-term financing

 

 

 

(75,000

)

 

 

Proceeds under other financing arrangements

 

2,285

 

 

3,404

 

 

3,377

 

Payments under other financing arrangements

 

(9,792

)

 

(9,856

)

 

(9,853

)

Payments related to tax withholding for stock-based compensation

 

(4,607

)

 

(3,900

)

 

(3,061

)

Repurchases of common shares

 

(32,112

)

 

(15,000

)

 

 

Payments of dividends

 

(104,159

)

 

(99,557

)

 

(99,416

)

Other

 

(6,478

)

 

(1,555

)

 

(4,331

)

Net cash flows provided (used) by financing activities

 

147,587

 

 

(231,464

)

 

(173,284

)

Effect of exchange rate changes on cash

 

7,870

 

 

(7,953

)

 

(19,843

)

Net change in cash and cash equivalents

 

424,294

 

 

51,297

 

 

(83,762

)

Cash and cash equivalents at beginning of year

 

670,980

 

 

619,683

 

 

703,445

 

Cash and cash equivalents at end of year

$

1,095,274

 

$

670,980

 

$

619,683

 

Income taxes paid (net of refunds)

$

75,342

 

$

66,372

 

$

87,009

 

Interest paid

 

57,041

 

 

53,607

 

 

54,576

 

CONSOLIDATED QUARTERLY FINANCIAL DATA
(Unaudited)
(Amounts in millions, except per share data)

2020

Quarter

4th

 

3rd

 

2nd

 

1st

Sales

$

985.3

$

924.3

$

925.0

$

893.5

 

Gross profit

 

295.4

 

285.2

 

269.7

 

266.5

 

Earnings before income taxes

 

61.3

 

72.3

 

16.7

 

36.5

 

Net earnings (loss) attributable to Flowserve Corporation

 

56.9

 

51.0

 

9.7

 

(1.3

)

Earnings (loss) per share(1):
Basic

$

0.44

$

0.39

$

0.07

$

(0.01

)

Diluted

$

0.43

$

0.39

$

0.07

$

(0.01

)

 
 

2019

Quarter

4th

 

3rd

 

2nd

 

1st

Sales

$

1,068.2

$

995.7

$

990.0

$

885.8

 

Gross profit

 

349.5

 

332.9

 

317.9

 

289.0

 

Earnings before income taxes

 

90.9

 

84.4

 

77.4

 

69.7

 

Net earnings attributable to Flowserve Corporation

 

72.6

 

59.8

 

54.0

 

52.4

 

Earnings per share (1):
Basic

$

0.55

$

0.46

$

0.41

$

0.40

 

Diluted

$

0.55

$

0.45

$

0.41

$

0.40

 

 
(1) Earnings per share is computed independently for each of the quarters presented. The sum of the quarters may not equal the total year amount due to the impact of changes in weighted average quarterly shares outstanding.

 

Investor Contacts:

Jay Roueche, Vice President, Investor Relations & Treasurer, (972) 443-6560

Mike Mullin, Director, Investor Relations, (972) 443-6636

Media Contact:

Lars Rosene, Vice President, Corporate Communications & Public Affairs, (972) 443-6644

KEYWORDS: United States North America Texas

INDUSTRY KEYWORDS: Engineering Chemicals/Plastics Utilities Oil/Gas Manufacturing Energy Other Manufacturing

MEDIA:

Logo
Logo

Tactile Systems Technology, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results; Introduces Full Year 2021 Outlook


Fourth Quarter Revenue Increased 4% Year-Over-Year

MINNEAPOLIS, Feb. 23, 2021 (GLOBE NEWSWIRE) — Tactile Systems Technology, Inc. (“Tactile Medical”) (Nasdaq: TCMD), a medical technology company focused on developing medical devices for the at-home treatment of chronic diseases, today reported financial results for the fourth quarter and full year ended December 31, 2020.


Fourth Quarter 2020 Summary:

  • Total revenue increased 4% year-over-year, to $59.2 million, compared to $57.1 million in fourth quarter 2019.
  • Operating income of $7.0 million, compared to $6.0 million in fourth quarter 2019.
  • Net income of $12.1 million, compared to $4.3 million in fourth quarter 2019.
  • Adjusted EBITDA of $10.8 million, compared to $10.4 million in fourth quarter 2019.
  • Cash, cash equivalents, and marketable securities of $47.9 million at December 31, 2020, compared to $45.2 million at December 31, 2019.


Full Year 2020 Summary:

  • Total revenue decreased 1% year-over-year, to $187.1 million, compared to $189.5 million in 2019.
  • Excluding the contribution to full year 2019 revenue related to the Company’s adoption of ASC 842, full year 2020 revenue reflects growth of 1% year-over-year on an operational basis.
  • Operating loss of $3.6 million, compared to operating income of $10.5 million in 2019.
  • Net loss of $0.6 million, compared to net income of $11.0 million in 2019.
  • Adjusted EBITDA of $16.0 million, compared to $25.3 million in 2019.

“We were pleased to close 2020 by returning to year-over-year growth in the fourth quarter, and ultimately exceeding the high end of our annual revenue guidance range, in spite of the business disruption that we experienced due to the COVID-19 pandemic,” said Dan Reuvers, President and Chief Executive Officer of Tactile Medical. “In the fourth quarter, the majority of the facilities that we serve continued to operate with constraints related to social distancing and safety protocols, and we experienced incremental headwinds during the month of December as the holiday wave of cases impacted clinicians, patients and our own team. In spite of these incremental headwinds, I am proud of the exceptional effort and dedication shown by our team during the quarter, which enabled us to deliver strong performance by continuing to support our existing customers while expanding our prescriber base.”

Mr. Reuvers added, “Despite the continuation of COVID-related headwinds as we enter 2021, we believe we are well-positioned to emerge with an enhanced sales and field support team in place to improve our coverage and the productivity of our representatives, as well as an expanded pool of prescribers and an updated approach for educating clinicians and training patients. We are focused on expanding our leadership position in the over $5 Billion U.S. lymphedema market through a combination of continued execution and strategic investment in our business with the goal of returning to sustained 20%+ revenue growth and improving profitability for the benefit of our patients, customers and shareholders.”


Fourth Quarter 2020 Financial Results

Total revenue in the fourth quarter of 2020 increased $2.2 million, or 4%, to $59.2 million, compared to $57.1 million in the fourth quarter of 2019. The increase in total revenue was attributable to an increase of $2.4 million, in sales and rentals of the Entre system, which was partially offset by a decrease of $0.3 million, in sales and rentals of the Flexitouch system in the quarter ended December 31, 2020. Fourth quarter revenue continued to be negatively impacted by COVID-19, primarily from social distancing requirements and safety protocols imposed within clinics. These headwinds were partially offset by the continued expansion of our commercial team, effective virtual educational events, and an increase in the number of Medicare patients served.

Gross profit in the fourth quarter of 2020 increased $0.8 million, or 2%, to $41.9 million, compared to $41.1 million in the fourth quarter of 2019. Gross margin was 71% of revenue, compared to 72% of revenue in the fourth quarter of 2019.

Operating expenses in the fourth quarter of 2020 decreased $0.2 million, or 1%, to $34.9 million, compared to $35.1 million in the fourth quarter of 2019. The decrease in operating expenses in the fourth quarter of 2020 was driven by a decrease in sales and marketing expense of $2.6 million, or 12%, to $19.8 million, primarily due to lower patient training costs, lower sales commissions and reduced travel and entertainment expenses. The decrease in sales and marketing expense was nearly fully offset by reimbursement, general and administrative expenses, which increased $2.2 million, or 19%, to $13.7 million, compared to $11.5 million in the fourth quarter of 2019. The increase in reimbursement, general and administrative expenses was driven by increased litigation defense costs and other professional fees, as well as personnel-related expenses due to increased headcount in our reimbursement and corporate functions.

Operating income in the fourth quarter of 2020 increased $1.0 million, or 16%, to $7.0 million, compared to $6.0 million in the fourth quarter of 2019.

Other income in the fourth quarter of 2020 increased $1.0 million to $1.2 million, compared to $0.2 million in the fourth quarter of 2019. The increase in other income was due to $1.2 million received under the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) Provider Relief Fund to provide relief for lost revenues from the COVID-19 public health emergency.

Income tax benefit in the fourth quarter of 2020 was $3.9 million, compared to income tax expense of $1.9 million in the fourth quarter of 2019. The year-over-year change in income tax benefit/expense was primarily due to changes in our effective tax rate, which was primarily attributable to a change in taxable income, including proportionately higher tax benefits for stock-based compensation as compared to the same period last year.

Net income in the fourth quarter of 2020 was $12.1 million, or $0.61 per diluted share, compared to net income of $4.3 million, or $0.22 per diluted share, in the fourth quarter of 2019. Weighted average shares used to compute diluted net income per share were 19.8 million and 19.7 million in the fourth quarters of 2020 and 2019, respectively.

Adjusted EBITDA was $10.8 million in the fourth quarter of 2020, compared to Adjusted EBITDA of $10.4 million in the fourth quarter of 2019.


Full Year 2020 Financial Results:

Total revenue for the twelve months ended December 31, 2020, decreased $2.4 million, or 1%, to $187.1 million, compared to $189.5 million for the twelve months ended December 31, 2019. Total revenue for the twelve months ended December 31, 2020, increased 1% on an operational basis, excluding the contribution to revenue in the twelve months ended December 31, 2019 related to the Company’s adoption of accounting standard, ASC 842. The decrease in total revenue on a reported basis for the twelve months ended December 31, 2020, was driven by a decrease of approximately $7.4 million, in sales and rentals of the Flexitouch system, offset in part by an increase of $5.0 million, in sales and rentals of the Entre system. Revenue in the first two months of 2020 was ahead of our expectations. Beginning in March 2020 and continuing through the fourth quarter, revenue was impacted by the COVID-19 pandemic, which limited our ability to access our clinician customers and their patients. Specifically, we saw healthcare facilities and clinics restricting access to their clinicians, reducing patient consultations, or closing temporarily due to COVID-19.

Net loss for the twelve months ended December 31, 2020 was $0.6 million, or $0.03 per diluted share, compared to net income of $11.0 million, or $0.56 per diluted share, for the twelve months ended December 31, 2019. Weighted average shares used to compute diluted net loss/income per share were 19.3 million and 19.6 million for the twelve months ended December 31, 2020 and 2019, respectively.

Adjusted EBITDA was $16.0 million in the twelve months ended December 31, 2020, compared to adjusted EBITDA of $25.3 million in the twelve months ended December 31, 2019.


Cash


Position

At December 31, 2020, cash, cash equivalents and marketable securities were $47.9 million, compared to $45.2 million at December 31, 2019. The Company had no outstanding borrowings on its $10.0 million revolving credit facility at December 31, 2020.


2021 Financial Outlook

The Company expects full year 2021 total revenue in the range of $215.3 million to $224.5 million, representing an increase of 15% to 20% year-over-year, compared to total revenue of $187.1 million in 2020.   


Conference Call

Management will host a conference call at 5:00 p.m. Eastern Time on February 23, 2021, to discuss the results of the quarter with a question-and-answer session. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13715783. A live webcast of the call will also be provided on the investor relations section of the Company’s website at investors.tactilemedical.com.

For those unable to participate, a replay of the call will be available for two weeks at 877-660-6853 (201-612-7415 for international callers); access code 13715783. The webcast will be archived at investors.tactilemedical.com.


About Tactile Systems Technology, Inc. (DBA Tactile Medical)

Tactile Medical is a leader in developing and marketing at-home therapy devices that treat chronic swelling conditions such as lymphedema and chronic venous insufficiency. Tactile Medical’s Mission is to help people suffering from chronic diseases live better and care for themselves at home. The Company’s unique offering includes advanced, clinically proven pneumatic compression devices, as well as continuity of care services provided by a national network of product specialists and trainers, reimbursement experts, patient advocates and clinicians. This combination of products and services ensures that tens of thousands of patients annually receive the at-home treatment necessary to better manage their chronic conditions. Tactile Medical takes pride in the fact that our solutions help increase clinical efficacy, reduce overall healthcare costs and improve the quality of life for patients with chronic conditions.


Legal Notice Regarding Forward-Looking Statements

This release contains forward-looking statements. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “continue,” “confident,” “outlook,” “guidance,” “project,” “goals,” “look forward,” “poised,” “designed,” “plan,” “return,” “focused,” “prospects” or “remain” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties outside of the Company’s control that can make such statements untrue, including, but not limited to, the impacts of the COVID-19 pandemic on the Company’s business, financial condition and results of operations; the course of the COVID-19 pandemic and its impact on general economic, business and market conditions; the Company’s inability to execute on its plans to respond to the COVID-19 pandemic; the adequacy of the Company’s liquidity to pursue its business objectives; the Company’s ability to obtain reimbursement from third party payers for its products; loss or retirement of key executives, including prior to identifying a successor; adverse economic conditions or intense competition; loss of a key supplier; entry of new competitors and products; adverse federal, state and local government regulation; technological obsolescence of the Company’s products; technical problems with the Company’s research and products; the Company’s ability to expand its business through strategic acquisitions; the Company’s ability to integrate acquisitions and related businesses; price increases for supplies and components; the effects of current and future U.S. and foreign trade policy and tariff actions; or the inability to carry out research, development and commercialization plans. In addition, other factors that could cause actual results to differ materially are discussed in the Company’s filings with the SEC. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company undertakes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.


Use of Non-GAAP Financial Measures

This press release includes the non-GAAP financial measures of Adjusted EBITDA, non-GAAP revenue change and Adjusted EBITDA margin, which differ from financial measures calculated in accordance with U.S. generally accepted accounting principles (“GAAP”).

Adjusted EBITDA in this release represents net income or loss, plus interest expense, net, or less interest income, net, less income tax benefit or plus income tax expense, plus depreciation and amortization, plus stock-based compensation expense, plus loss on termination of lease, plus impairment charges and inventory write-offs, less CARES Act funding, plus litigation defense costs and plus executive transition costs. Adjusted EBITDA margin in this release represents net margin (net income or loss divided by total revenue), plus or less the same items as with Adjusted EBITDA, but on a percentage of revenue basis. Reconciliations of Adjusted EBITDA to net income (loss), and Adjusted EBITDA margin to net margin, are included in this press release.

Non-GAAP revenue change in this release represents full year 2020 revenue compared to full year 2019 revenue less operating lease revenue that was recognized in 2019 in connection with the Company’s adoption of ASC 842. A reconciliation of GAAP revenue change to non-GAAP revenue change is included in this press release.

These non-GAAP financial measures are presented because the Company believes they are useful indicators of its operating performance. Management uses these measures principally as measures of the Company’s operating performance and for planning purposes, including the preparation of the Company’s annual operating plan and financial projections. The Company believes these measures are useful to investors as supplemental information and because they are frequently used by analysts, investors and other interested parties to evaluate companies in its industry. The Company also believes these non-GAAP financial measures are useful to its management and investors as a measure of comparative operating performance from period to period. In addition, Adjusted EBITDA is used as a performance metric in the Company’s compensation program.

Adjusted EBITDA, non-GAAP revenue change and Adjusted EBITDA margin are non-GAAP financial measures and should not be considered as an alternative to, or superior to, net income or loss, GAAP revenue change or net margin, respectively, as measures of financial performance or cash flows from operations as a measure of liquidity, or any other performance measure derived in accordance with GAAP, and they should not be construed to imply that the Company’s future results will be unaffected by unusual or non-recurring items. In addition, Adjusted EBITDA is not intended to be a measure of free cash flow for management’s discretionary use, as it does not reflect certain cash requirements such as tax payments, debt service requirements, capital expenditures and certain other cash costs that may recur in the future. Adjusted EBITDA contains certain other limitations, including the failure to reflect our cash expenditures, cash requirements for working capital needs and cash costs to replace assets being depreciated and amortized. In evaluating non-GAAP financial measures, you should be aware that in the future the Company may incur expenses that are the same as or similar to some of the adjustments in this presentation. The Company’s presentation of non-GAAP financial measures should not be construed to imply that its future results will be unaffected by any such adjustments. Management compensates for these limitations by primarily relying on the Company’s GAAP results in addition to using non-GAAP financial measures on a supplemental basis. The Company’s definition of these non-GAAP financial measures is not necessarily comparable to other similarly titled captions of other companies due to different methods of calculation.

 
 
Tactile Systems Technology, Inc.
Consolidated Balance Sheets
(Unaudited)
      December 31,      December 31,
(In thousands, except share and per share data)     2020      2019

Assets
           
Current assets            
Cash and cash equivalents   $ 47,855   $ 22,770
Marketable securities         22,464
Accounts receivable     43,849     33,444
Net investment in leases     10,708     8,147
Inventories     18,563     19,059
Prepaid expenses and other current assets     2,638     2,451
Total current assets     123,613     108,335
Non-current assets            
Property and equipment, net     6,957     7,408
Right of use operating lease assets     20,132     15,885
Intangible assets, net     1,680     5,312
Accounts receivable, non-current     9,433     4,184
Deferred income taxes     10,198     8,970
Other non-current assets     2,074     1,658
Total non-current assets     50,474     43,417
Total assets   $ 174,087   $ 151,752

Liabilities and Stockholders’ Equity
           
Current liabilities            
Accounts payable   $ 4,197   $ 3,843
Accrued payroll and related taxes     11,588     10,098
Accrued expenses     4,423     4,498
Income taxes payable     2,658     632
Operating lease liabilities     2,006     1,454
Other current liabilities     1,842     903
Total current liabilities     26,714     21,428
Non-current liabilities            
Accrued warranty reserve, non-current     3,235     2,541
Income taxes, non-current         54
Operating lease liabilities, non-current     19,388     15,134
Total non-current liabilities     22,623     17,729
Total liabilities     49,337     39,157
             
Stockholders’ equity:            
Preferred stock, $0.001 par value, 50,000,000 shares authorized; none issued
and outstanding as of December 31, 2020 and December 31, 2019
       
Common stock, $0.001 par value, 300,000,000 shares authorized; 19,492,718
shares issued and outstanding as of December 31, 2020; 19,152,715 shares
issued and outstanding as of December 31, 2019
    19     19
Additional paid-in capital     104,675     91,874
Retained earnings     20,056     20,676
Accumulated other comprehensive income         26
Total stockholders’ equity     124,750     112,595
Total liabilities and stockholders’ equity   $ 174,087   $ 151,752
             

Tactile Systems Technology, Inc.
Consolidated Statements of Operations
(Unaudited)
                         
    Three Months Ended   Year Ended
    December 31,


  December 31,
(In thousands, except share and per share data)   2020
     2019


     2020
     2019
Revenue                        
Sales revenue   $ 51,784     $ 50,401   $ 161,497     $ 162,904
Rental revenue     7,458       6,662     25,633       26,588
Total revenue     59,242       57,063     187,130       189,492
Cost of revenue                        
Cost of sales revenue     14,441       13,803     45,309       47,034
Cost of rental revenue     2,948       2,160     9,011       8,222
Total cost of revenue     17,389       15,963     54,320       55,256
Gross profit                        
Gross profit – sales revenue     37,343       36,598     116,188       115,870
Gross profit – rental revenue     4,510       4,502     16,622       18,366
Gross profit     41,853       41,100     132,810       134,236
Operating expenses                        
Sales and marketing     19,777       22,374     79,634       78,920
Research and development     1,373       1,192     5,264       5,174
Reimbursement, general and administrative     13,712       11,485     51,540       39,644
Total operating expenses     34,862       35,051     136,438       123,738
Income (loss) from operations     6,991       6,049     (3,628 )     10,498
Other income     1,187       151     1,367       631
Income (loss) before income taxes     8,178       6,200     (2,261 )     11,129
Income tax (benefit) expense     (3,935 )     1,917     (1,641 )     158
Net income (loss)   $ 12,113     $ 4,283   $ (620 )   $ 10,971
Net income (loss) per common share                        
Basic   $ 0.62     $ 0.22   $ (0.03 )   $ 0.58
Diluted   $ 0.61     $ 0.22   $ (0.03 )   $ 0.56
Weighted-average common shares used to
compute net income (loss) per common
share
                       
Basic     19,458,865       19,062,584     19,346,929       18,919,007
Diluted     19,830,970       19,700,882     19,346,929       19,641,143
                             

             
Tactile Systems Technology, Inc.
Consolidated Statements of Cash Flows
(Unaudited)
   
    Year Ended December 31, 
(In thousands)     2020        2019 
Cash flows from operating activities            
Net (loss) income   $ (620 )   $ 10,971  
Adjustments to reconcile net (loss) income to net cash provided by operating activities:            
Depreciation and amortization     2,794       3,538  
Net amortization of premiums and discounts on securities available-for-sale     (91 )     (307 )
Deferred income taxes     (1,233 )     (146 )
Stock-based compensation expense     10,689       9,824  
Gain on other investments and maturities of marketable securities     (11 )     7  
Impairment losses     4,025        
Loss on termination of lease           1,148  
Changes in assets and liabilities:            
Accounts receivable     (10,405 )     (9,112 )
Net investment in leases     (2,561 )     (8,147 )
Inventories     318       (7,870 )
Income taxes     1,972       2,428  
Prepaid expenses and other assets     (528 )     (1,166 )
Right of use operating lease assets     559       625  
Medicare accounts receivable, non-current     (5,249 )     (2,300 )
Accounts payable     337       (1,389 )
Accrued payroll and related taxes     1,490       2,677  
Accrued expenses and other liabilities     1,308       1,729  
   Net cash provided by operating activities     2,794       2,510  
Cash flows from investing activities            
Proceeds from sales of securities available-for-sale           1,493  
Proceeds from maturities of securities available-for-sale     22,500       25,000  
Purchases of securities available-for-sale           (22,840 )
Purchases of property and equipment     (2,059 )     (5,446 )
Intangible assets costs     (232 )     (542 )
Other investments     (30 )      
   Net cash provided by (used in) investing activities     20,179       (2,335 )
Cash flows from financing activities            
Taxes paid for net share settlement of restricted stock units     (1,854 )     (3,391 )
Proceeds from exercise of common stock options     1,068       2,834  
Proceeds from the issuance of common stock from the employee stock purchase plan     2,898       3,053  
   Net cash provided by financing activities     2,112       2,496  
Net increase in cash and cash equivalents     25,085       2,671  
Cash and cash equivalents – beginning of period     22,770       20,099  
Cash and cash equivalents – end of period   $ 47,855     $ 22,770  
             
Supplemental cash flow disclosure            
Cash paid for interest   $     $  
Cash paid for taxes   $ 543     $ 344  
Capital expenditures incurred but not yet paid   $ 17     $ 122  
                 

The following table summarizes revenue by product for the three and twelve months ended December 31, 2020 and 2019:
 
Tactile Systems Technology, Inc.
Supplemental Financial Information
(Unaudited)
                                                 
    Three Months Ended       Year Ended    
    December 31,   Change   December 31,   Change
(Dollars in thousands)      2020      2019      $      %      2020      2019      $      %
Flexitouch System   $ 51,293   $ 51,556   $ (263 )   (1 ) %   $ 163,914   $ 171,323   $ (7,409 )   (4 ) %
Other products(1)     7,949     5,507     2,442     44   %     23,216     18,169     5,047     28   %
Total Revenue   $ 59,242   $ 57,063   $ 2,179     4   %   $ 187,130   $ 189,492   $ (2,362 )   (1 ) %
                                                         
 
(1) The “other products” line primarily includes revenue from our Entre system. The Actitouch system and Airwear wrap contributed immaterial amounts of revenue for the years ended December 31, 2020 and 2019.

The following table contains a reconciliation of the revenue change rate to the non-GAAP revenue change rate for the year ended December 31, 2020 compared to the year ended December 31, 2019:
 
Tactile Systems Technology, Inc.
Reconciliation of Revenue Change Rate to Non-GAAP Revenue Change Rate
(Unaudited)
                 
                 
    Year Ended   Year Ended   Change Rate
(Dollars in thousands)   December 31, 2020   December 31, 2019   % Change
Total revenue   $ 187,130   $ 189,492     (1 ) %
Less: Operating lease revenue(1)     N/A     (5,018 )   2   %
Total non-GAAP revenue   $ 187,130   $ 184,474     1   %
                       
(1)  The operating lease revenue excluded from revenue for the year ended December 31, 2019, in the adjustment was related to rental agreements commencing prior to December 31, 2018, which were recognized as month-to-month operating leases for the year ended December 31, 2019, and did not contribute to the Company’s revenue results in 2020.

The following table contains a reconciliation of net income (loss) to Adjusted EBITDA for the three and twelve months ended December 31, 2020 and 2019, as well as the dollar and percentage change between the comparable periods:
 
Tactile Systems Technology, Inc.
Reconciliation of Net Income (Loss) to Non-GAAP Adjusted EBITDA
(Unaudited)
                                                 
    Three Months Ended   Increase   Year Ended   Increase
    December 31,   (Decrease)   December 31,   (Decrease)
(Dollars in thousands)      2020        2019     $      %      2020        2019     $      %
Net income (loss)   $ 12,113     $ 4,283     $ 7,830     183   %   $ (620 )   $ 10,971     $ (11,591 )   (106 ) %
Interest expense (income), net     (14 )     (81 )     67     (83 ) %     (75 )     (343 )     268     (78 ) %
Income tax expense (benefit)     (3,935 )     1,917       (5,852 )   N.M.   %     (1,641 )     158       (1,799 )   N.M.   %
Depreciation and amortization     692       730       (38 )   (5 ) %     2,794       3,538       (744 )   (21 ) %
Stock-based compensation     2,401       2,437       (36 )   (1 ) %     10,689       9,824       865     9   %
Loss on termination of lease           1,148       (1,148 )   (100 ) %           1,148       (1,148 )   (100 ) %
Impairment charges and inventory write-offs                       %     4,025             4,025       %
CARES Act Funding     (1,176 )           (1,176 )     %     (1,176 )           (1,176 )     %
Litigation defense costs     599             599       %     1,030             1,030       %
Executive transition costs     105             106       %     981             981       %
Adjusted EBITDA   $ 10,785     $ 10,434     $ 352     3   %   $ 16,007     $ 25,296     $ (9,289 )   (37 ) %
                                                                 

The following table contains a reconciliation of net margin to Adjusted EBITDA margin for the three and twelve months ended December 31, 2020 and 2019, as well as the basis point change between the comparable periods:
Tactile Systems Technology, Inc.
Reconciliation of Net Margin to Adjusted EBITDA Margin
(Unaudited)
                                     
    Three Months Ended         Year Ended      
    December 31,   Increase   December 31,   Increase
(As a percentage of revenue)      2020      2019   (Decrease)      2020      2019   (Decrease)
Net margin   20.4   %   7.5   %   1,290   bps   (0.3 ) %   5.8   %   (610 ) bps
Interest expense (income), net   0.0   %   (0.1 ) %   10   bps   0.0   %   (0.2 ) %   20   bps
Income tax expense (benefit)   (6.6 ) %   3.4   %   (1,000 ) bps   (0.9 ) %   0.1   %   (100 ) bps
Depreciation and amortization   1.2   %   1.3   %   (10 ) bps   1.5   %   1.9   %   (40 ) bps
Stock-based compensation   4.1   %   4.3   %   (20 ) bps   5.7   %   5.2   %   50   bps
Loss on termination of lease   0.0   %   1.9   %   (190 ) bps   0.0   %   0.5   %   (50 ) bps
Impairment charges and inventory write-offs   0.0   %   0.0   %     bps   2.2   %   0.0   %   220   bps
CARES Act Funding   (2.0 ) %   0.0   %   (200 ) bps   (0.6 ) %   0.0   %   (60 ) bps
Litigation defense costs   0.9   %   0.0   %   90   bps   0.6   %   0.0   %   60   bps
Executive transition costs   0.2   %   0.0   %   20   bps   0.4   %   0.0   %   40   bps
Adjusted EBITDA margin   18.2   %   18.3   %   (10 ) bps   8.6   %   13.3   %   (470 ) bps



Investor Inquiries:
Mike Piccinino, CFA
Managing Director
Westwicke Partners
443-213-0500
[email protected]

LSB Industries, Inc. Provides Update on Operational Status of Facilities

LSB Industries, Inc. Provides Update on Operational Status of Facilities

OKLAHOMA CITY, Okla.–(BUSINESS WIRE)–
LSB Industries, Inc. (“LSB” or “the Company”), (NYSE: LXU), today announced that on Sunday, February 21, 2021 it began the phased restart of its Pryor, OK facility (“Pryor”), which was taken out of service on February 12, 2021 after extreme cold weather caused a surge in natural gas prices in the region, along with the curtailment of gas distribution by the operator of the pipeline that supplies natural gas to Pryor.

As weather across the middle of the country has improved and temperatures have warmed, natural gas prices have normalized and supply volumes have been restored to levels required for full operation of the Company’s facilities. Pryor is in the the process of restarting and LSB management expects the facility to return to pre-shutdown production volume levels as safely and as soon as practicable.

Also as a result of unprecedented cold weather conditions, on February 17, 2021, the primary natural gas supplier to LSB’s El Dorado, AR facility (“El Dorado”) asserted a claim of force majeure and materially restricted the supply of gas to El Dorado. However, effective today, the force majeure has been lifted and El Dorado’s ammonia plant is currently in production and in process of ramping up to full rates.

Notably, the Company’s Cherokee, AL facility was not materially impacted by the extreme cold weather and related natural gas price and supply issues and operated at targeted levels throughout February.

About LSB Industries, Inc.

LSB Industries, Inc., headquartered in Oklahoma City, Oklahoma, manufactures and sells chemical products for the agricultural, mining, and industrial markets. The Company owns and operates facilities in Cherokee, Alabama, El Dorado, Arkansas and Pryor, Oklahoma, and operates a facility for a global chemical company in Baytown, Texas. LSB’s products are sold through distributors and directly to end customers primarily throughout the United States. Additional information about the Company can be found on its website at www.lsbindustries.com.

Forward-Looking Statements

Statements in this release that are not historical are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements, which are subject to known and unknown risks, uncertainties and assumptions about us, may include projections of our future financial performance including the effects of the COVID-19 pandemic and anticipated performance based on our growth and other strategies and anticipated trends in our business. These statements are only predictions based on our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance or actual achievements to differ materially from the results, level of activity, performance or anticipated achievements expressed or implied by the forward-looking statements. Significant risks and uncertainties may relate to, but are not limited to, business and market disruptions related to the COVID-19 pandemic, market conditions and price volatility for our products and feedstocks, as well as global and regional economic downturns, including as a result of the COVID-19 pandemic, that adversely affect the demand for our end-use products; disruptions in production at our manufacturing facilities; and other financial, economic, competitive, environmental, political, legal and regulatory factors. These and other risk factors are discussed in the Company’s filings with the Securities and Exchange Commission (SEC).

Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for our management to predict all risks and uncertainties, nor can management assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance or achievements. Neither we nor any other person assumes responsibility for the accuracy or completeness of any of these forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Unless otherwise required by applicable laws, we undertake no obligation to update or revise any forward-looking statements, whether because of new information or future developments.

Company Contact:

Mark Behrman, President & CEO

Cheryl Maguire, Executive Vice President & CFO

(405) 235-4546

Investor Contact: The Equity Group Inc.

Fred Buonocore, CFA (212) 836-9607

Mike Gaudreau (212) 836-9620

KEYWORDS: United States North America Oklahoma

INDUSTRY KEYWORDS: Agriculture Natural Resources Manufacturing Mining/Minerals Chemicals/Plastics

MEDIA:

Logo
Logo

Recro to Report Fourth Quarter and Year-End 2020 Financial Results Earlier Than Previously Announced

Conference Call and Webcast Moved Up to 8:00 a.m. Eastern on Friday, February 26

MALVERN, Pa., Feb. 23, 2021 (GLOBE NEWSWIRE) — Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced that it moved up the time of its previously announced quarterly earnings release and conference call.   The company will now report its financial results for the fourth quarter and year-end 2020 prior to the opening of the market on Friday, February 26, 2021, as opposed to post-market on that day. Recro’s management team will then host a conference call and audio webcast at 8:00 a.m. ET on Friday, February 26, 2021 to discuss the financial results and recent operational highlights.

To access the live conference call please dial (844) 243-4691 from the U.S. or (225) 283-0379 from outside the U.S. at least ten minutes prior to the start time and reference conference ID 3352999. Those interested in listening to the conference call live via webcast may do so by visiting the “Events” page in the Investor section of the Company’s website, www.recrocdmo.com. In addition, an archived webcast will be available on the Company’s website approximately two hours after the event and will be available for 30 days.

About Recro

Recro (NASD: REPH) is a contract development and manufacturing organization (CDMO) with capabilities from early feasibility to commercial manufacturing. With an expertise in solving complex manufacturing problems, Recro is a leading CDMO providing oral solid dosage form development, end-to-end regulatory support, clinical and commercial manufacturing, and packaging and logistics services to the global pharmaceutical market.

In addition to our experience in handling DEA controlled substances and developing and manufacturing modified release oral solid dosage forms, Recro has the expertise to deliver on our clients’ pharmaceutical development and manufacturing projects, regardless of complexity level. We do all of this in our best-in-class facilities, which total 120,000 square feet, in Gainesville, Georgia.

For more information about Recro’s CDMO solutions, visit recrocdmo.com.

 



Contacts:
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
[email protected]

Tim Brons (Media)
Vida Strategic Partners
415-675-7402
[email protected]

Ryan D. Lake (CFO)
Recro
(484) 395-2436
[email protected]

IAA SignsCEO Action for Diversity and Inclusion™ Pledge

IAA SignsCEO Action for Diversity and Inclusion™ Pledge

Represents First Company in the Vehicle Salvage Industry to Join Coalition

WESTCHESTER, Ill.–(BUSINESS WIRE)–
IAA, Inc. (NYSE: IAA), a leading global digital marketplace connecting vehicle buyers and sellers, announces IAA CEO and President John Kett has signed the CEO Action for Diversity and Inclusion™ pledge, the largest CEO-driven business coalition to advance diversity and inclusion within the workplace. As the first signatory in the vehicle salvage industry, IAA joins over 1,600 of the world’s leading companies and business organizations in making this significant commitment.

“We believe diversity, equity, and inclusion are the lifeblood of a thriving business, and we recognize that organizations can have a significant impact when it comes to effecting change in society,” said IAA CEO and President John Kett. “By ensuring diverse social, economic, and cultural identities are represented and empowered throughout our organization, IAA will be best able to serve our customers and foster a culture of innovation.”

As part of the company’s pledge, IAA has created the Diversity, Equity, and Inclusion Council (the “IAA DEI Council”) to cultivate a workplace where different perspectives and experiences are welcomed and respected. Leading the council are IAA executives: Sidney Peryar, Executive Vice President and Chief Legal Counsel; Jeanene O’Brien, Sr. Vice President of Global Marketing and Communications; and Bill Davidson, Sr. Vice President and Head of Human Resources. The IAA DEI Council is engaging members across the global IAA team and focusing on three key areas: cultural awareness and inclusion, pay equity, and industry partnership.

The CEO Action for Diversity & Inclusion coalition represents 85 industries across all 50 U.S. states and millions of employees globally, while serving as a hub for information sharing, idea generation, and program development. With more than 1,200 best-known actions shared, the coalition is cultivating a new type of ecosystem centered on collaboration and sharing.

About CEO Action for Diversity & Inclusion™

CEO Action for Diversity & Inclusion™ is the largest CEO-driven business commitment to advance diversity and inclusion within the workplace. Bringing together more than 1,600 CEOs of America’s leading organizations, the commitment outlines actions that participating companies pledge to take to cultivate a workplace where diverse perspectives and experiences are welcomed and respected, employees feel comfortable and encouraged to discuss diversity and inclusion, and where best known—and unsuccessful—actions can be shared across organizations. Learn more at CEOAction.com and connect with us on Twitter: @CEOAction.

About IAA

IAA, Inc. (NYSE: IAA) is a leading global digital marketplace connecting vehicle buyers and sellers. Leveraging leading-edge technology and focusing on innovation, IAA’s unique platform facilitates the marketing and sale of total-loss, damaged and low-value vehicles. Headquartered near Chicago in Westchester, Illinois, IAA has nearly 4,000 employees and more than 200 facilities throughout the U.S., Canada, and the United Kingdom. IAA serves a global buyer base – located throughout over 170 countries – and a full spectrum of sellers, including insurers, dealerships, fleet lease and rental car companies, and charitable organizations. Buyers have access to multiple digital bidding and buying channels, innovative vehicle merchandising, and efficient evaluation services, enhancing the overall purchasing experience. IAA offers sellers a comprehensive suite of services aimed at maximizing vehicle value, reducing administrative costs, shortening selling cycle time, and delivering the highest economic returns. For more information visit IAAI.com, and follow IAA on Facebook, Twitter, Instagram, YouTube, and LinkedIn.

IAA Contacts

Media Inquiries:

Jeanene O’Brien | IAA, Inc.

SVP, Global Marketing and Communications

(708) 492-7328

[email protected]

Analyst Inquiries:

Arif Ahmed | IAA, Inc.

VP, Treasury

(708) 492-7257

[email protected]

Caitlin Churchill | ICR

(203) 682-8200

[email protected]

KEYWORDS: United States North America Illinois

INDUSTRY KEYWORDS: Online Retail Retail Automotive General Automotive Other Automotive Other Retail

MEDIA:

CubeSmart Declares First Quarter 2021 Dividend

MALVERN, Pa., Feb. 23, 2021 (GLOBE NEWSWIRE) — CubeSmart (NYSE: CUBE) a self-administered and self-managed real estate investment trust focused on self-storage properties, announced today that its Board of Trustees declared a quarterly dividend of $0.34 per common share for the period ending March 31, 2021. The dividend is payable on April 15, 2021 to common shareholders of record on April 1, 2021.

About the Company

CubeSmart is a self-administered and self-managed real estate investment trust. CubeSmart owns or manages 1,240 self-storage properties across the United States. According to the 2020 Self Storage Almanac, CubeSmart is one of the top three owners and operators of self-storage properties in the U.S.

The Company’s mission is to simplify the organizational and logistical challenges created by the many life events and business needs of its customers through innovative solutions, unparalleled service, and genuine care. The Company’s self-storage properties are designed to offer affordable, easily accessible, and, in most locations, climate-controlled storage space for residential and commercial customers.

For more information about business and personal storage or to learn more about the Company and find a nearby storage facility, visit www.cubesmart.com or call CubeSmart toll free at 800-800-1717.

Company Contact:
CubeSmart
Josh Schutzer
Senior Director, Finance
610-535-5700